<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/sitemap.xsl"?>
<!--Generated by the Simple XML Sitemap Drupal module: https://drupal.org/project/simple_sitemap.-->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
 <url>
  <loc>https://investor.regeneron.com/</loc>
  <lastmod>2025-02-27T11:40:45-05:00</lastmod>
  <changefreq>daily</changefreq>
  <priority>1.0</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/committee-details/audit-committee</loc>
  <lastmod>2023-09-11T12:42:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/committee-details/compensation-committee</loc>
  <lastmod>2022-10-07T11:13:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/committee-details/technology-committee</loc>
  <lastmod>2023-09-11T13:02:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/committee-details/corporate-governance-and-compliance-committee</loc>
  <lastmod>2022-10-07T11:14:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/asrs-2018</loc>
  <lastmod>2018-08-27T19:38:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/ash-2018</loc>
  <lastmod>2018-12-01T12:15:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/37th-annual-jp-morgan-healthcare-conference</loc>
  <lastmod>2019-02-19T19:47:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q4-2018-earnings-conference-call</loc>
  <lastmod>2019-02-19T19:52:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/angiogenesis-exudation-and-degeneration-2019</loc>
  <lastmod>2019-02-09T16:29:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/cowen-39th-annual-healthcare-conference</loc>
  <lastmod>2019-03-11T09:01:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2019-aaaai-annual-meeting</loc>
  <lastmod>2019-02-25T12:45:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/asco-sitc-2019</loc>
  <lastmod>2019-03-01T09:58:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jp-morgan-2019-spring-biotech-conference-call-series</loc>
  <lastmod>2019-03-11T17:25:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/annual-shareholder-meeting</loc>
  <lastmod>2019-06-14T13:56:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q1-2019-earnings-conference-call</loc>
  <lastmod>2019-04-08T16:30:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bank-america-merrill-lynch-healthcare-conference</loc>
  <lastmod>2019-04-30T13:54:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/barclays-biopharmaceuticals-ceocfo-conference-call-series</loc>
  <lastmod>2019-05-09T16:10:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/ubs-global-healthcare-conference</loc>
  <lastmod>2019-04-30T13:58:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/goldman-sachs-global-healthcare-conference</loc>
  <lastmod>2019-06-11T10:29:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/american-society-clinical-oncology-asco-2019-annual-meeting</loc>
  <lastmod>2019-06-01T14:17:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/european-hematology-association-eha-2019-annual-meeting</loc>
  <lastmod>2019-06-15T10:45:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q2-2019-earnings-conference-call</loc>
  <lastmod>2019-07-08T09:54:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/morgan-stanley-17th-annual-global-healthcare-conference</loc>
  <lastmod>2019-09-06T16:04:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/pegs-boston-summit-presentation-april-2019</loc>
  <lastmod>2019-09-26T17:00:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/european-society-medical-oncology-esmo-congress-2019</loc>
  <lastmod>2019-09-30T12:17:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q3-2019-earnings-conference-call</loc>
  <lastmod>2019-10-18T11:49:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/credit-suisse-28th-annual-healthcare-conference</loc>
  <lastmod>2019-10-28T12:33:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jefferies-2019-london-healthcare-conference</loc>
  <lastmod>2019-11-18T11:13:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-oncology-strategy</loc>
  <lastmod>2019-11-07T16:40:47-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/guggenheim-healthcare-talks-idea-forum-neuroimmunology-day</loc>
  <lastmod>2019-11-14T14:50:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/piper-jaffray-31st-annual-healthcare-conference</loc>
  <lastmod>2019-11-22T10:36:22-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/american-society-hematology-ash-2019-annual-meeting</loc>
  <lastmod>2019-12-09T16:46:56-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/overview-sanofi-ownership-regeneron-common-stock</loc>
  <lastmod>2019-12-11T17:12:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/38th-annual-jp-morgan-healthcare-conference</loc>
  <lastmod>2020-01-13T03:55:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/38th-annual-jp-morgan-healthcare-conference-breakout-session</loc>
  <lastmod>2019-12-20T16:31:04-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q4-2019-earnings-conference-call</loc>
  <lastmod>2020-01-14T05:23:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/angiogenesis-exudation-and-degeneration-2020</loc>
  <lastmod>2020-02-09T14:14:51-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/svb-leerink-9th-annual-global-healthcare-conference</loc>
  <lastmod>2020-02-12T20:36:22-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/cowen-40th-annual-healthcare-conference</loc>
  <lastmod>2020-03-02T10:59:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/barclays-global-healthcare-conference</loc>
  <lastmod>2020-03-09T14:23:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/corporate-presentation-feb-2020</loc>
  <lastmod>2020-02-20T10:27:49-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jp-morgan-2020-biotech-conference-call-series</loc>
  <lastmod>2020-03-03T18:59:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/oppenheimer-30th-annual-healthcare-conference</loc>
  <lastmod>2020-03-09T14:31:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/acc20</loc>
  <lastmod>2020-03-30T16:40:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2020-annual-meeting-shareholders</loc>
  <lastmod>2020-06-12T12:34:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/updates-regeneron-accounting</loc>
  <lastmod>2020-04-06T17:05:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q1-2020-earnings-conference-call</loc>
  <lastmod>2020-05-05T06:41:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bank-america-securities-virtual-health-care-conference</loc>
  <lastmod>2020-05-04T15:18:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/rbc-capital-markets-virtual-global-healthcare-conference</loc>
  <lastmod>2020-05-12T08:44:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bernsteins-36th-annual-strategic-decisions-conference</loc>
  <lastmod>2020-05-20T12:07:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-oncology-investor-event-asco-2020</loc>
  <lastmod>2022-06-02T14:25:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/goldman-sachs-41st-annual-global-healthcare-conference</loc>
  <lastmod>2020-06-08T23:27:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/credit-suisse-biotech-management-board-call-series</loc>
  <lastmod>2020-06-17T13:57:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bmo-2020-prescriptions-success-healthcare-conference</loc>
  <lastmod>2020-06-17T14:04:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/european-hematology-association-eha-2020</loc>
  <lastmod>2020-06-12T13:01:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q2-2020-earnings-conference-call</loc>
  <lastmod>2020-07-08T16:33:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-corporate-presentation-2</loc>
  <lastmod>2020-08-12T16:04:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/citis-15th-annual-biopharma-virtual-conference</loc>
  <lastmod>2020-09-03T15:03:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/morgan-stanley-18th-annual-global-healthcare-conference</loc>
  <lastmod>2020-09-03T16:44:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/cantor-fitzgerald-virtual-global-healthcare-conference</loc>
  <lastmod>2020-09-03T15:20:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/european-respiratory-society-ers-2020-virtual-congress</loc>
  <lastmod>2020-09-08T19:00:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-covid-19-program-update</loc>
  <lastmod>2020-09-29T18:11:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q3-2020-earnings-conference-call</loc>
  <lastmod>2020-10-07T07:54:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/credit-suisse-29th-annual-virtual-healthcare-conference</loc>
  <lastmod>2020-11-04T10:35:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/cowen-virtual-presentation-series-2020-io-next-summit</loc>
  <lastmod>2020-11-04T10:37:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jefferies-virtual-london-healthcare-conference</loc>
  <lastmod>2020-11-04T10:41:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/focis-federation-clinical-immunology-societies-2020-annual-meeting</loc>
  <lastmod>2020-10-31T11:23:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-corporate-presentation-3</loc>
  <lastmod>2020-11-06T11:30:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/piper-sandler-32nd-annual-virtual-healthcare-conference</loc>
  <lastmod>2020-11-23T17:55:59-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/evercore-isi-3rd-annual-healthconx-conference-0</loc>
  <lastmod>2020-11-20T09:44:04-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-oncology-investor-event-ash-2020</loc>
  <lastmod>2020-12-07T16:42:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q4-2020-earnings-conference-call</loc>
  <lastmod>2021-03-15T09:33:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/39th-annual-jp-morgan-healthcare-conference</loc>
  <lastmod>2021-01-11T08:24:04-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/svb-leerink-10th-annual-global-healthcare-conference</loc>
  <lastmod>2021-03-15T09:15:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/cowen-41st-annual-health-care-conference</loc>
  <lastmod>2021-03-15T09:16:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/barclays-global-healthcare-conference-0</loc>
  <lastmod>2021-03-15T09:17:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/oppenheimer-31st-annual-healthcare-conference</loc>
  <lastmod>2021-03-16T08:58:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q1-2021-earnings-conference-call</loc>
  <lastmod>2021-05-05T23:21:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2021-annual-meeting-shareholders</loc>
  <lastmod>2021-06-11T12:51:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regen-covtm-data-non-hospitalized-covid-19-patients</loc>
  <lastmod>2021-04-14T07:40:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bank-america-securities-virtual-health-care-conferenc</loc>
  <lastmod>2021-05-07T15:50:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/rbc-capital-markets-virtual-global-healthcare-conference-0</loc>
  <lastmod>2021-05-13T17:35:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2021-american-society-clinical-oncology-asco-annual-meeting</loc>
  <lastmod>2022-05-26T10:14:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bernsteins-37th-annual-strategic-decisions-conference</loc>
  <lastmod>2022-05-26T10:14:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/goldman-sachs-42nd-annual-global-healthcare-conference</loc>
  <lastmod>2022-05-26T10:15:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bmo-biopharma-day</loc>
  <lastmod>2022-05-26T10:16:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/baird-sustainability-conference</loc>
  <lastmod>2021-06-17T08:30:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/guggenheim-biopharma-strategy-series-biopharmas-next-decade-views-top-global</loc>
  <lastmod>2022-05-26T10:17:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q2-2021-earnings-conference-call</loc>
  <lastmod>2022-05-26T10:17:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/morgan-stanley-19th-annual-global-healthcare-conference</loc>
  <lastmod>2022-05-26T10:18:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/cantor-fitzgerald-virtual-global-healthcare-conference-0</loc>
  <lastmod>2022-05-26T10:24:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-oncology-investor-event-esmo-2021</loc>
  <lastmod>2022-05-26T10:19:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q3-2021-earnings-conference-call</loc>
  <lastmod>2022-05-26T10:24:50-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-investor-event-ash-2021</loc>
  <lastmod>2022-05-26T10:28:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/evercore-isi-4th-annual-healthconx-conference</loc>
  <lastmod>2022-05-26T10:25:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/piper-sandler-33rd-annual-healthcare-conference</loc>
  <lastmod>2022-05-26T10:26:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/hc-wainwright-co-unlocking-full-potential-rnai-world-class-novel-target</loc>
  <lastmod>2022-05-26T10:27:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q4-2021-earnings-conference-call</loc>
  <lastmod>2022-05-26T10:31:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/40th-annual-jp-morgan-healthcare-conference</loc>
  <lastmod>2022-05-26T10:30:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/angiogenesis-exudation-and-degeneration-2022</loc>
  <lastmod>2022-04-25T03:42:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/cowen-42nd-annual-health-care-conference</loc>
  <lastmod>2022-05-26T10:32:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/oppenheimer-32nd-annual-healthcare-conference</loc>
  <lastmod>2022-05-26T10:33:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/barclays-global-healthcare-conference-1</loc>
  <lastmod>2022-05-26T10:33:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q1-2022-earnings-conference-call</loc>
  <lastmod>2022-05-26T10:34:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2022-annual-meeting-shareholders</loc>
  <lastmod>2022-10-24T10:57:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bofa-securities-healthcare-conference</loc>
  <lastmod>2022-05-26T10:34:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/goldman-sachs-43rd-annual-global-healthcare-conference</loc>
  <lastmod>2022-06-06T16:52:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-purchase-sanofis-stake-libtayo-investor-call</loc>
  <lastmod>2022-06-02T08:14:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q2-2022-earnings-conference-call</loc>
  <lastmod>2022-08-02T23:28:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/esmo-2022</loc>
  <lastmod>2023-05-12T16:24:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2022-wells-fargo-healthcare-conference</loc>
  <lastmod>2022-08-29T17:36:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/morgan-stanley-20th-annual-global-healthcare-conference</loc>
  <lastmod>2022-08-29T17:35:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q3-2022-earnings-conference-call</loc>
  <lastmod>2022-11-03T00:16:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/american-academy-ophthalmology-2022-annual-meeting</loc>
  <lastmod>2022-09-30T16:27:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-investor-event-ash-2022</loc>
  <lastmod>2022-12-13T17:19:09-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/retina-society-55th-annual-scientific-meeting</loc>
  <lastmod>2022-11-04T13:46:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jefferies-london-healthcare-conference</loc>
  <lastmod>2022-11-09T12:46:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/5th-annual-evercore-isi-healthconx-conference</loc>
  <lastmod>2022-12-19T09:57:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/piper-sandler-34th-annual-healthcare-conference</loc>
  <lastmod>2022-11-09T15:44:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q4-2022-earnings-conference-call</loc>
  <lastmod>2023-02-07T18:42:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/41st-annual-jp-morgan-healthcare-conference</loc>
  <lastmod>2023-01-13T08:40:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/svb-securities-global-biopharma-conference</loc>
  <lastmod>2023-02-15T16:35:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/cowen-43rd-annual-health-care-conference</loc>
  <lastmod>2023-03-08T12:43:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/oppenheimer-33rd-annual-healthcare-conference</loc>
  <lastmod>2023-03-21T17:12:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/barclays-global-healthcare-conference-2</loc>
  <lastmod>2023-03-21T17:12:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q1-2023-earnings-conference-call</loc>
  <lastmod>2023-06-09T09:45:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2023-annual-meeting-shareholders</loc>
  <lastmod>2023-06-09T10:43:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/bofa-securities-2023-health-care-conference</loc>
  <lastmod>2023-06-09T13:40:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2023-rbc-capital-markets-global-healthcare-conference</loc>
  <lastmod>2023-06-09T15:19:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/td-cowen-4th-annual-oncology-innovation-summit</loc>
  <lastmod>2023-06-09T17:10:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jefferies-healthcare-conference</loc>
  <lastmod>2023-06-09T17:55:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/goldman-sachs-44th-annual-global-healthcare-conference</loc>
  <lastmod>2023-08-11T10:10:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q2-2023-earnings-conference-call</loc>
  <lastmod>2023-08-11T14:06:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/american-society-retina-specialists-annual-meeting-2-year-96-week-data-phase</loc>
  <lastmod>2023-07-28T14:31:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2023-wells-fargo-healthcare-conference</loc>
  <lastmod>2023-09-07T14:37:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/morgan-stanley-21st-annual-global-healthcare-conference</loc>
  <lastmod>2023-09-15T12:20:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q3-2023-earnings-conference-call</loc>
  <lastmod>2023-11-06T16:10:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/23rd-european-society-retina-specialists-euretina-congress-60-week-and-2-year</loc>
  <lastmod>2023-10-03T09:19:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/truist-securities-biopharma-symposium</loc>
  <lastmod>2023-11-14T16:28:54-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/ubs-biopharma-conference</loc>
  <lastmod>2023-11-14T10:30:47-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jefferies-london-healthcare-conference-0</loc>
  <lastmod>2024-01-22T10:15:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-investor-event-ash-2023</loc>
  <lastmod>2024-01-18T14:28:41-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/piper-sandler-35th-annual-healthcare-conference</loc>
  <lastmod>2024-01-18T14:27:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/42nd-annual-jp-morgan-healthcare-conference</loc>
  <lastmod>2024-01-18T14:26:53-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q4-2023-earnings-conference-call</loc>
  <lastmod>2025-02-05T10:18:53-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/oppenheimer-34th-annual-healthcare-life-sciences-conference</loc>
  <lastmod>2024-02-22T14:24:03-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/td-cowen-44th-annual-health-care-conference</loc>
  <lastmod>2024-03-14T17:14:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/barclays-26th-annual-global-healthcare-conference</loc>
  <lastmod>2024-03-29T11:04:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/leerink-partners-global-biopharma-conference</loc>
  <lastmod>2024-03-21T13:48:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q1-2024-earnings-conference-call</loc>
  <lastmod>2024-06-07T15:08:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2024-annual-meeting-shareholders</loc>
  <lastmod>2024-10-29T23:28:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/rbc-capital-markets-global-healthcare-conference</loc>
  <lastmod>2024-06-07T15:17:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jefferies-global-healthcare-conference</loc>
  <lastmod>2024-06-07T15:06:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/goldman-sachs-45th-annual-global-healthcare-conference</loc>
  <lastmod>2024-06-13T13:48:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q2-2024-earnings-conference-call</loc>
  <lastmod>2024-08-05T18:08:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/morgan-stanley-22nd-annual-global-healthcare-conference</loc>
  <lastmod>2024-09-17T12:49:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/2024-wells-fargo-healthcare-conference</loc>
  <lastmod>2024-09-17T10:36:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-investor-event-esmo-2024</loc>
  <lastmod>2024-09-17T12:23:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q3-2024-earnings-conference-call</loc>
  <lastmod>2024-11-05T15:35:06-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/jefferies-london-healthcare-conference-1</loc>
  <lastmod>2025-01-03T09:37:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/piper-sandler-36th-annual-healthcare-conference</loc>
  <lastmod>2025-01-03T09:36:49-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/43rd-annual-jp-morgan-healthcare-conference</loc>
  <lastmod>2025-02-06T11:37:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/regeneron-pharmaceuticals-q4-2024-earnings-conference-call</loc>
  <lastmod>2025-02-06T10:33:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/td-cowen-45th-annual-health-care-conference</loc>
  <lastmod>2025-03-10T11:56:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events/event-details/leerink-partners-2025-global-healthcare-conference</loc>
  <lastmod>2025-03-12T13:54:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/investor-relations</loc>
  <lastmod>2025-02-27T11:40:45-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news/press-releases</loc>
  <lastmod>2024-12-04T14:59:16-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events-and-presentations/events-and-recent</loc>
  <lastmod>2025-01-02T10:45:50-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/governance/governance-documents</loc>
  <lastmod>2024-12-04T18:23:14-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/governance/committee-composition</loc>
  <lastmod>2024-12-04T18:26:56-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/governance/contact-the-board</loc>
  <lastmod>2024-12-04T18:36:17-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/financials/overview</loc>
  <lastmod>2024-12-06T14:54:40-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/financials/sec-filings</loc>
  <lastmod>2024-12-06T14:55:02-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/financials/annual-reports-and-proxy-statements</loc>
  <lastmod>2024-12-06T14:55:28-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/stock-information/ownership-profile</loc>
  <lastmod>2024-12-04T16:25:50-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/stock-information</loc>
  <lastmod>2024-12-04T16:13:05-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/stock-information/historic-stock-lookup</loc>
  <lastmod>2024-12-04T16:15:23-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/stock-information/investment-calculator</loc>
  <lastmod>2024-12-04T16:19:34-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/resources/investor-faqs</loc>
  <lastmod>2024-12-04T18:40:59-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/email-alerts</loc>
  <lastmod>2018-06-13T07:11:10-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/financials/quarterly-results</loc>
  <lastmod>2024-12-06T14:55:51-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/governance/insider-transactions</loc>
  <lastmod>2024-12-04T18:38:41-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/email-alerts-subscription</loc>
  <lastmod>2018-06-13T07:05:43-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news/media-statements</loc>
  <lastmod>2025-02-03T16:15:34-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/events-and-presentations/archive</loc>
  <lastmod>2024-12-09T19:45:21-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sitemap</loc>
  <lastmod>2025-02-25T17:15:38-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-aventis-and-regeneron-announce-results-phase-2-study</loc>
  <lastmod>2009-07-02T14:58:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-converts-interleukin-1-antibody-opt-rights-royalty</loc>
  <lastmod>2009-07-02T14:59:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-8th-annual-needham-life</loc>
  <lastmod>2009-07-02T15:00:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-leerink-swann-novel-cancer</loc>
  <lastmod>2009-07-02T15:01:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-deutsche-bank-34th-annual</loc>
  <lastmod>2009-07-02T15:02:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2009-financial-and-operating</loc>
  <lastmod>2009-07-02T15:04:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/bayer-and-regeneron-extend-development-program-vegf-trap-eye</loc>
  <lastmod>2009-07-02T15:10:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-university-texas-southwestern-medical-center</loc>
  <lastmod>2009-07-02T15:11:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-university-texas-southwestern-medical-center-0</loc>
  <lastmod>2009-07-02T15:14:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-initiation-phase-3-gout-program-arcalystr</loc>
  <lastmod>2009-07-02T15:15:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-cowen-and-company-29th-annual</loc>
  <lastmod>2009-07-02T15:16:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-barclays-capital-global</loc>
  <lastmod>2009-07-02T15:17:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-participation-panel-discussion-rbc-capital</loc>
  <lastmod>2009-07-02T15:24:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-20th-annual-piper-jaffray</loc>
  <lastmod>2009-07-02T15:25:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-credit-suisse-2008-healthcare</loc>
  <lastmod>2009-07-02T15:26:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/vegf-trap-eye-final-phase-2-results-age-related-macular</loc>
  <lastmod>2009-07-02T15:27:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-ubs-global-life-sciences</loc>
  <lastmod>2009-07-02T15:28:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-columbia-university-enter-strategic-velocimmuner</loc>
  <lastmod>2009-07-02T15:29:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-morgan-stanley-global</loc>
  <lastmod>2009-07-06T07:17:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-arcalystr-rilonacept-reduced-incidence-gout-flares-81</loc>
  <lastmod>2009-07-06T07:19:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-webcast-presentation-results-phase-2-study</loc>
  <lastmod>2009-07-06T07:20:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-healthcare-announce-vegf-trap-eye-achieved</loc>
  <lastmod>2009-07-06T07:21:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/key-studies-published-supporting-fda-approval-regenerons</loc>
  <lastmod>2009-07-06T07:22:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-28th-annual-canaccord-adams</loc>
  <lastmod>2009-07-06T07:23:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-velocigener-agreement-sanofi-aventis</loc>
  <lastmod>2009-07-06T07:24:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-bmo-capital-markets-2008-focus</loc>
  <lastmod>2009-07-06T07:25:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-jefferies-2nd-annual-healthcare</loc>
  <lastmod>2009-07-06T07:26:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-needham-seventh-annual</loc>
  <lastmod>2009-07-06T07:27:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-aventis-and-regeneron-update-aflibercept-vegf-trap</loc>
  <lastmod>2009-07-06T07:28:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-citi-investment-research-global</loc>
  <lastmod>2009-07-06T07:29:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/bayer-and-regeneron-dose-first-patient-second-phase-3-study-vegf</loc>
  <lastmod>2009-07-06T07:30:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-healthcare-announce-encouraging-32-week</loc>
  <lastmod>2009-07-06T07:32:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-morgan-stanley-global-0</loc>
  <lastmod>2009-07-06T07:33:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/arcalysttm-rilonacept-first-and-only-fda-approved-treatment</loc>
  <lastmod>2009-07-06T07:34:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-lehman-brothers-global</loc>
  <lastmod>2009-07-06T07:35:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-regenerons-arcalysttm-rilonacept-treatment</loc>
  <lastmod>2009-07-06T07:36:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-merrill-lynch-global</loc>
  <lastmod>2009-07-06T07:37:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-jp-morgan-healthcare-conference</loc>
  <lastmod>2009-07-06T07:37:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-closes-312-million-common-stock-sale-connection-sanofi</loc>
  <lastmod>2009-07-06T07:38:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-participation-panel-discussion-rbc-capital-0</loc>
  <lastmod>2009-07-06T07:42:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-initiates-major-global-collaboration-sanofi-aventis</loc>
  <lastmod>2009-07-06T07:43:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-credit-suisse-healthcare</loc>
  <lastmod>2009-07-06T07:43:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/pdufa-date-rilonacept-il-1-trap-extended-three-months-fda</loc>
  <lastmod>2009-07-06T07:45:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-primary-endpoint-results-phase-2</loc>
  <lastmod>2009-07-06T07:46:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-ubs-global-life-sciences-0</loc>
  <lastmod>2009-07-06T07:47:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-results-exploratory-proof-concept</loc>
  <lastmod>2009-07-06T07:48:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-webcast-presentations-two-investor-conferences</loc>
  <lastmod>2009-07-06T07:49:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-oncology-program-aflibercept-vegf-trap-initiated</loc>
  <lastmod>2009-07-06T07:50:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-receives-20-million-milestone-payment-initiation-phase</loc>
  <lastmod>2009-07-06T07:50:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/rilonacept-il-1-trap-granted-fda-priority-review-treatment-caps</loc>
  <lastmod>2009-07-06T07:51:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-healthcare-initiate-phase-3-global</loc>
  <lastmod>2009-07-06T08:25:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-submits-biologics-license-application-us-fda-il-1-trap</loc>
  <lastmod>2009-07-06T08:30:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-webcast-presentations-two-investor-conferences-0</loc>
  <lastmod>2009-07-06T08:33:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/results-vegf-trap-aflibercept-highlighted-asco-2007-annual</loc>
  <lastmod>2009-07-06T08:34:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/vegf-trap-eye-phase-2-wet-amd-results-reported-arvo-annual</loc>
  <lastmod>2009-07-06T08:35:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-morgan-stanley-global-1</loc>
  <lastmod>2009-07-06T08:36:50-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/astellas-licenses-regenerons-velocimmuner-technology-discovering</loc>
  <lastmod>2009-07-06T08:37:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-interim-phase-2-data-reported-vegf-trap-eye-age-related</loc>
  <lastmod>2009-07-06T08:40:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-present-lehman-brothers-10th-annual-global-healthcare</loc>
  <lastmod>2009-07-06T08:44:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-expands-commercial-and-clinical-capabilities-through</loc>
  <lastmod>2009-07-06T08:45:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-vegf-trap-clinical-update</loc>
  <lastmod>2009-07-06T08:46:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/astrazeneca-licenses-regenerons-velocimmuner-technology</loc>
  <lastmod>2009-07-06T08:47:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-25th-annual-jpmorgan-healthcare</loc>
  <lastmod>2009-07-06T08:48:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-full-year-and-fourth-quarter-2008-financial</loc>
  <lastmod>2009-07-16T10:16:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2008-financial-and-operating</loc>
  <lastmod>2009-07-16T10:18:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2008-financial-and-operating</loc>
  <lastmod>2009-07-16T10:20:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2008-financial-and-operating</loc>
  <lastmod>2009-07-16T10:21:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2007-financial</loc>
  <lastmod>2009-07-16T10:22:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-financial-and-operating-results</loc>
  <lastmod>2009-07-16T10:24:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-financial-and-operating-results</loc>
  <lastmod>2009-07-16T10:26:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-financial-and-operating-results</loc>
  <lastmod>2009-07-16T10:27:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2006-financial</loc>
  <lastmod>2009-07-16T10:30:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-aventis-and-regeneron-announce-results-phase-2-study-0</loc>
  <lastmod>2009-08-12T09:07:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/first-patient-enrolled-regeneron-and-bayer-healthcare-vegf-trap</loc>
  <lastmod>2009-08-12T09:08:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-receives-european-medicines-agency-positive-opinion</loc>
  <lastmod>2009-08-12T09:09:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2009-financial-and-operating</loc>
  <lastmod>2009-08-12T09:10:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-29th-annual-canaccord-adams</loc>
  <lastmod>2009-08-12T09:51:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-september-2009-investment-conference</loc>
  <lastmod>2009-09-10T12:34:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-aflibercept-metastatic-pancreatic-cancer</loc>
  <lastmod>2009-09-11T12:07:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/enrollment-completed-regeneron-and-bayer-healthcare-phase-3</loc>
  <lastmod>2009-09-14T03:01:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-pharmaceuticals-and-biomed-realty-trust-host-ribbon</loc>
  <lastmod>2009-10-06T13:11:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-18th-annual-credit-suisse</loc>
  <lastmod>2009-10-27T05:31:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-rilonacept-granted-european-marketing-authorization</loc>
  <lastmod>2009-10-27T12:31:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2009-financial-and-operating</loc>
  <lastmod>2009-11-03T02:04:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-conference-call-discuss-expanded-antibody</loc>
  <lastmod>2009-11-10T11:37:05-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-aventis-and-regeneron-expand-strategic-antibody</loc>
  <lastmod>2009-11-12T06:40:48-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-21st-annual-piper-jaffray</loc>
  <lastmod>2009-11-24T04:34:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-deutsche-bank-2009-biotech</loc>
  <lastmod>2009-12-10T04:31:11-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-28th-annual-jp-morgan</loc>
  <lastmod>2010-01-07T04:34:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/vegf-trap-eye-shows-positive-results-phase-2-study-patients</loc>
  <lastmod>2010-02-18T02:04:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-full-year-and-fourth-quarter-2009-financial</loc>
  <lastmod>2010-02-18T03:34:19-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-participation-panel-discussion-rbc-capital-1</loc>
  <lastmod>2010-02-25T04:31:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-cowen-and-company-30th-annual</loc>
  <lastmod>2010-03-04T04:31:37-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-barclays-capital-global-2010</loc>
  <lastmod>2010-03-18T05:34:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-appointment-michael-aberman-md-vice</loc>
  <lastmod>2010-03-22T12:31:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2010-financial-and-operating</loc>
  <lastmod>2010-04-29T03:05:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-bank-america-merrill-lynch-2010</loc>
  <lastmod>2010-05-07T05:31:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-participation-j-p-morgan-biotech-ceocfo</loc>
  <lastmod>2010-05-11T12:34:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-initial-data-two-antibody-product-candidates</loc>
  <lastmod>2010-05-12T04:55:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-2010-citi-investment-research</loc>
  <lastmod>2010-05-20T05:31:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-9th-annual-needham-healthcare</loc>
  <lastmod>2010-06-04T05:31:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-schedules-june-9-2010-teleconference-and-webcast</loc>
  <lastmod>2010-06-08T13:22:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/arcalystr-rilonacept-meets-primary-and-all-secondary-endpoints</loc>
  <lastmod>2010-06-09T02:58:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-goldman-sachs-31st-annual</loc>
  <lastmod>2010-06-11T05:31:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-webcast-investor-day-july-15-2010</loc>
  <lastmod>2010-07-13T04:49:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2010-financial-and-operating</loc>
  <lastmod>2010-07-27T23:01:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/astellas-pay-295-million-extend-license-regenerons-velocimmuner</loc>
  <lastmod>2010-07-27T23:01:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-bank-america-merrill-lynch-0</loc>
  <lastmod>2010-08-05T05:31:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-morgan-stanley-global-2</loc>
  <lastmod>2010-09-03T05:31:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-aflibercept-second-line-metastatic-colorectal</loc>
  <lastmod>2010-09-08T12:01:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-ubs-global-life-sciences-1</loc>
  <lastmod>2010-09-13T05:31:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-panel-discussion-citis-5th-annual-biotech</loc>
  <lastmod>2010-09-28T05:37:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-pharmaceuticals-inc-announces-sale-4500000-shares</loc>
  <lastmod>2010-10-06T12:22:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-increases-size-public-offering-common-stock</loc>
  <lastmod>2010-10-08T04:04:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-exercise-over-allotment-option-and-closing</loc>
  <lastmod>2010-10-13T05:37:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-17th-annual-newsmakers-biotech</loc>
  <lastmod>2010-10-15T05:31:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2010-financial-results-and</loc>
  <lastmod>2010-10-28T03:13:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-2010-credit-suisse-annual</loc>
  <lastmod>2010-11-02T05:43:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/christine-poon-elected-regeneron-board-directors</loc>
  <lastmod>2010-11-15T04:04:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-schedules-november-22-2010-teleconference-and-webcast</loc>
  <lastmod>2010-11-19T11:33:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/bayer-and-regeneron-report-positive-top-line-results-two-phase-3</loc>
  <lastmod>2010-11-22T02:46:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-22nd-annual-piper-jaffray</loc>
  <lastmod>2010-11-23T04:33:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-2010-deutsche-bank-biofest</loc>
  <lastmod>2010-12-06T04:33:22-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-schedules-december-20-2010-teleconference-and-webcast</loc>
  <lastmod>2010-12-19T20:12:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-29th-annual-jp-morgan</loc>
  <lastmod>2011-01-03T04:35:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-start-phase-3-trial-extend-ophthalmology</loc>
  <lastmod>2011-01-17T21:03:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-isi-annual-conference</loc>
  <lastmod>2011-02-08T04:33:17-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-report-positive-results-vegf-trap-eye-phase</loc>
  <lastmod>2011-02-08T10:43:05-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-webcast-investor-briefing-vegf-trap-eye-clinical</loc>
  <lastmod>2011-02-09T04:04:11-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-full-year-and-fourth-quarter-2010-financial</loc>
  <lastmod>2011-02-17T02:03:53-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-submits-biologics-license-application-fda-vegf-trap</loc>
  <lastmod>2011-02-22T03:04:53-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-march-2011-investor-conference-presentations</loc>
  <lastmod>2011-02-23T04:33:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/arcalystr-rilonacept-meets-primary-and-all-secondary-endpoints-0</loc>
  <lastmod>2011-02-28T02:33:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-aventis-and-regeneron-report-top-line-results-phase-iii</loc>
  <lastmod>2011-03-10T11:06:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-10th-annual-needham-healthcare</loc>
  <lastmod>2011-03-30T05:33:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-announce-start-phase-3-clinical-program</loc>
  <lastmod>2011-04-08T05:00:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-grants-priority-review-vegf-trap-eye-treatment-wet-age</loc>
  <lastmod>2011-04-18T03:34:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-aventis-and-regeneron-report-positive-phase-iii-results</loc>
  <lastmod>2011-04-26T12:07:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-report-positive-results-vegf-trap-eye-second</loc>
  <lastmod>2011-04-27T12:15:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-bank-america-merrill-lynch-2011</loc>
  <lastmod>2011-05-02T05:33:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2011-financial-and-operating</loc>
  <lastmod>2011-05-03T03:04:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-schedules-advisory-committee-meeting-discuss-bla-vegf-trap</loc>
  <lastmod>2011-05-23T08:15:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/zaltraptm-aflibercept-significantly-improved-survival-previously</loc>
  <lastmod>2011-06-05T21:03:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/vegf-trap-eye-submitted-eu-marketing-authorization-treatment-wet</loc>
  <lastmod>2011-06-06T22:33:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-president-and-ceo-leonard-s-schleifer-named-ernst</loc>
  <lastmod>2011-06-13T12:45:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/trading-regeneron-common-stock-halted</loc>
  <lastmod>2011-06-17T03:06:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-eyleatm-aflibercept-ophthalmic-solution</loc>
  <lastmod>2011-06-17T10:06:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eyleatm-aflibercept-injection-submitted-japan-marketing</loc>
  <lastmod>2011-06-28T19:03:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-pharmaceuticals-inc-announces-r-unit-program-help</loc>
  <lastmod>2011-06-30T06:48:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-zaltraptm-aflibercept-advanced-prostate-cancer</loc>
  <lastmod>2011-07-07T03:03:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-phase-2b-trial-results</loc>
  <lastmod>2011-07-12T12:06:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2011-financial-and-operating</loc>
  <lastmod>2011-07-28T03:06:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-review-biologics-license-application-eyleatm</loc>
  <lastmod>2011-08-16T13:12:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-clinical-presentations-asrs-2011-annual</loc>
  <lastmod>2011-08-17T12:06:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-september-2011-investor-conference</loc>
  <lastmod>2011-08-31T05:33:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-appointment-joseph-j-larosa-senior-vice</loc>
  <lastmod>2011-09-06T03:03:50-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-ranked-science-magazine-2-employer-global</loc>
  <lastmod>2011-09-15T12:03:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-zaltrapr-clinical-presentation-european</loc>
  <lastmod>2011-09-23T03:03:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-pharmaceuticals-announces-proposed-offering</loc>
  <lastmod>2011-10-17T12:09:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-pharmaceuticals-announces-pricing-offering-convertible</loc>
  <lastmod>2011-10-18T06:03:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2011-financial-and-operating</loc>
  <lastmod>2011-10-27T03:06:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-phase-2b-results-sarilumab-rheumatoid-arthritis-be</loc>
  <lastmod>2011-10-27T04:04:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-2011-credit-suisse-annual</loc>
  <lastmod>2011-11-07T04:33:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-preliminary-phase-2-program</loc>
  <lastmod>2011-11-10T01:24:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/rockefeller-university-president-marc-tessier-lavigne-elected</loc>
  <lastmod>2011-11-21T04:04:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-approval-eylea153-aflibercept-injection</loc>
  <lastmod>2011-11-21T16:03:37-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-acceptance-arcalystr-rilonacept</loc>
  <lastmod>2011-11-22T04:36:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations</loc>
  <lastmod>2011-11-23T04:33:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-initiate-phase-3-clinical-program-treatment</loc>
  <lastmod>2011-11-27T21:03:28-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-time-change-2011-deutsche-bank</loc>
  <lastmod>2011-12-01T06:03:22-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/two-year-results-phase-3-studies-eyleatm-aflibercept-injection</loc>
  <lastmod>2011-12-05T04:47:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-host-conference-call-january-3-830-am-eastern-time</loc>
  <lastmod>2012-01-02T12:21:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-settlement-patent-litigation-genentech-us</loc>
  <lastmod>2012-01-03T02:03:28-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-30th-annual-j-p-morgan</loc>
  <lastmod>2012-01-03T04:33:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-full-year-2011-financial-and-operating-results</loc>
  <lastmod>2012-01-26T11:03:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-february-13-2012-date-full-year-2011</loc>
  <lastmod>2012-02-10T11:06:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2011-financial</loc>
  <lastmod>2012-02-13T02:03:41-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-leerink-swann-2012-global</loc>
  <lastmod>2012-02-13T11:06:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-february-2012-investor-conference</loc>
  <lastmod>2012-02-21T11:07:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-march-2012-investor-conference-presentations</loc>
  <lastmod>2012-02-28T11:07:00-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-announce-approval-eylear-aflibercept</loc>
  <lastmod>2012-03-07T23:03:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-change-date-presentation-barclays-capital</loc>
  <lastmod>2012-03-09T04:33:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-data-publication-and-presentations-potential</loc>
  <lastmod>2012-03-21T13:03:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-phase-2-data-potential-first-class</loc>
  <lastmod>2012-03-26T08:53:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-regulatory-and-clinical-update</loc>
  <lastmod>2012-04-04T21:03:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2012-financial-and-operating</loc>
  <lastmod>2012-04-12T12:06:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2012-financial-and-operating</loc>
  <lastmod>2012-04-26T02:33:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-announce-co-promotion-agreement-santen</loc>
  <lastmod>2012-05-07T22:03:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-fda-advisory-committee-discussion</loc>
  <lastmod>2012-05-08T13:06:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-participation-j-p-morgan-biotech-ceocfo-0</loc>
  <lastmod>2012-05-09T05:33:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-bank-america-merrill-lynch-2012</loc>
  <lastmod>2012-05-10T05:33:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-publication-positive-phase-2</loc>
  <lastmod>2012-05-29T13:18:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-june-2012-investor-conference-presentations</loc>
  <lastmod>2012-05-30T05:33:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2012-financial-and-operating</loc>
  <lastmod>2012-07-11T05:33:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-launch-comprehensive-phase-3-clinical</loc>
  <lastmod>2012-07-20T04:46:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2012-financial-and-operating</loc>
  <lastmod>2012-07-25T02:33:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-receives-complete-response-letter-fda-arcalystr</loc>
  <lastmod>2012-07-30T15:27:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/us-fda-approves-zaltrapr-ziv-aflibercept-after-priority-review</loc>
  <lastmod>2012-08-03T11:24:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-september-2012-investor-conference</loc>
  <lastmod>2012-08-29T05:33:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-recommended-approval-treatment-wet</loc>
  <lastmod>2012-09-21T05:24:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-named-worlds-1-biopharmaceutical-employer-science</loc>
  <lastmod>2012-09-21T08:15:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-approval-eylear-aflibercept-injection</loc>
  <lastmod>2012-09-21T10:09:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-approved-treatment-wet-age-related</loc>
  <lastmod>2012-09-28T00:12:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2012-financial-and-operating</loc>
  <lastmod>2012-10-10T05:33:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-publication-eylear-aflibercept-injection</loc>
  <lastmod>2012-10-18T12:13:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2012-financial-and-operating</loc>
  <lastmod>2012-10-24T02:33:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-publication-phase-2-results-ldl</loc>
  <lastmod>2012-10-31T13:03:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-patient-enrollment-cardiovascular</loc>
  <lastmod>2012-11-05T03:07:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-november-2012-investor-conference</loc>
  <lastmod>2012-11-06T11:33:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/zaltrapr-ziv-aflibercept-receives-chmp-positive-opinion-european</loc>
  <lastmod>2012-11-16T02:48:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-approved-treatment-wet-age-0</loc>
  <lastmod>2012-11-26T21:18:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-deutsche-bank-2012-dbaccess</loc>
  <lastmod>2012-11-27T04:33:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-named-biotechnology-company-year</loc>
  <lastmod>2012-11-29T09:18:11-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-submitted-eu-marketing-authorization</loc>
  <lastmod>2012-12-05T21:03:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-january-2013-investor-conference</loc>
  <lastmod>2012-12-20T04:33:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-recommends-rejection-mini-tender-offer-trc-capital</loc>
  <lastmod>2013-01-04T11:42:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2012-financial-and</loc>
  <lastmod>2013-01-28T11:08:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/zaltrapr-ziv-aflibercept-approved-eu-patients-previously-treated</loc>
  <lastmod>2013-02-05T09:06:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-receipt-hart-scott-rodino-notice</loc>
  <lastmod>2013-02-11T04:36:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2012-financial</loc>
  <lastmod>2013-02-14T01:33:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-initiate-phase-3-trial-eylear-aflibercept</loc>
  <lastmod>2013-02-18T21:33:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2013-investor-conference</loc>
  <lastmod>2013-02-19T04:33:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-proof-concept-data</loc>
  <lastmod>2013-03-02T04:00:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-potential-additional-royalty-stream-related</loc>
  <lastmod>2013-03-04T04:04:43-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-pharmaceuticals-announces-expansion-new-yorks-hudson</loc>
  <lastmod>2013-04-04T05:18:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2013-financial-and-operating</loc>
  <lastmod>2013-04-11T12:06:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2013-investor-conference-0</loc>
  <lastmod>2013-04-18T05:33:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-acquires-full-rights-two-novel-ophthalmology</loc>
  <lastmod>2013-05-03T02:33:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2013-financial-and-operating</loc>
  <lastmod>2013-05-03T02:33:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2013-investor-conference-1</loc>
  <lastmod>2013-05-08T05:33:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-patient-enrollment-two-phase-3</loc>
  <lastmod>2013-05-14T21:03:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-publication-positive-phase-2a</loc>
  <lastmod>2013-05-21T04:18:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-report-positive-phase-3-results-eylear</loc>
  <lastmod>2013-06-05T22:33:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-first-recipients-annual-regeneron-prize</loc>
  <lastmod>2013-06-27T12:33:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2013-financial-and-operating</loc>
  <lastmod>2013-07-02T12:06:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-recommended-approval-treatment</loc>
  <lastmod>2013-07-26T05:04:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2013-financial-and-operating</loc>
  <lastmod>2013-08-05T22:33:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-report-positive-one-year-results-two-phase-3</loc>
  <lastmod>2013-08-05T22:33:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-granted-fundamental-patents-covering-mouse-antibody</loc>
  <lastmod>2013-08-07T12:22:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2013-investor-conference-2</loc>
  <lastmod>2013-08-27T06:09:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-approved-europe-treatment-visual</loc>
  <lastmod>2013-08-28T22:30:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-appointment-robert-e-landry-senior-vice</loc>
  <lastmod>2013-09-10T04:05:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-present-phase-3-data-eylear-aflibercept-injection</loc>
  <lastmod>2013-09-17T12:06:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2013-financial-and-operating</loc>
  <lastmod>2013-10-10T12:07:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-top-line-results-alirocumab</loc>
  <lastmod>2013-10-15T21:03:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-positive-phase-3-data-eylear-aflibercept</loc>
  <lastmod>2013-10-21T03:04:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-named-top-employer-global-biopharmaceutical-industry</loc>
  <lastmod>2013-10-24T12:03:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2013-investor-conference-3</loc>
  <lastmod>2013-11-01T05:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2013-financial-and-operating</loc>
  <lastmod>2013-11-05T01:33:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-submitted-eu-marketing</loc>
  <lastmod>2013-11-07T01:05:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlights-eylear-aflibercept-injection-data-be</loc>
  <lastmod>2013-11-12T11:07:47-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-results-sarilumab-first</loc>
  <lastmod>2013-11-21T20:03:09-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-approved-treatment-macular-edema</loc>
  <lastmod>2013-11-21T21:03:16-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-chief-executive-officer-and-chief-scientific-officer</loc>
  <lastmod>2013-11-25T02:04:17-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regenerons-dupilumab-named-clinical-advance-year</loc>
  <lastmod>2013-11-25T02:04:19-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2013-investor-conference-4</loc>
  <lastmod>2013-12-04T04:30:47-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-32nd-annual-j-p-morgan</loc>
  <lastmod>2013-12-17T04:30:49-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-acceptance-eylear-aflibercept-injection</loc>
  <lastmod>2013-12-18T02:33:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-collaboration-american-college</loc>
  <lastmod>2013-12-18T20:00:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-amendment-investor-agreement-sanofi</loc>
  <lastmod>2014-01-12T21:03:47-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-geisinger-health-system-announce-major-human</loc>
  <lastmod>2014-01-13T03:07:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-launches-new-human-genetics-initiative</loc>
  <lastmod>2014-01-13T03:07:26-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-develop-new-treatment-option-wet-age-related</loc>
  <lastmod>2014-01-13T11:06:49-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2013-financial-and</loc>
  <lastmod>2014-01-21T04:34:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/two-year-results-phase-3-vista-trial-eylear-aflibercept</loc>
  <lastmod>2014-02-10T02:33:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2013-financial</loc>
  <lastmod>2014-02-11T01:33:23-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2014-investor-conference</loc>
  <lastmod>2014-02-14T04:30:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-acceptance-eylear-aflibercept-0</loc>
  <lastmod>2014-02-24T02:30:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/bayer-healthcare-and-regeneron-announce-regulatory-submission</loc>
  <lastmod>2014-03-02T21:00:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-present-alirocumab-clinical-data-american</loc>
  <lastmod>2014-03-26T22:03:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-report-positive-results-alirocumab-phase-2</loc>
  <lastmod>2014-04-01T04:09:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-initiative-stem-education-hudson-valley</loc>
  <lastmod>2014-04-03T12:00:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/robert-ingram-elected-regeneron-board-directors</loc>
  <lastmod>2014-04-04T12:03:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2014-financial-and-operating</loc>
  <lastmod>2014-04-11T05:30:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2014-investor-conference-0</loc>
  <lastmod>2014-05-02T05:30:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-avalanche-biotechnologies-announce-collaboration</loc>
  <lastmod>2014-05-05T04:30:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2014-financial-and-operating</loc>
  <lastmod>2014-05-08T02:30:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-update-upcoming-2014-investor-conference</loc>
  <lastmod>2014-05-30T12:06:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-winners-2014-regeneron-prize-creative</loc>
  <lastmod>2014-06-02T13:06:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-submitted-eu-marketing-0</loc>
  <lastmod>2014-06-10T22:30:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-new-detailed-data-positive</loc>
  <lastmod>2014-06-11T21:00:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-recommended-approval-treatment-0</loc>
  <lastmod>2014-06-27T03:18:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-results-phase-2b-study</loc>
  <lastmod>2014-07-09T13:00:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/two-year-results-phase-3-vivid-dme-trial-eylear-aflibercept</loc>
  <lastmod>2014-07-18T02:00:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2014-financial-and-operating</loc>
  <lastmod>2014-07-18T12:03:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-approval-treatment</loc>
  <lastmod>2014-07-29T14:33:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-report-positive-top-line-results-nine-phase</loc>
  <lastmod>2014-07-30T04:01:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-plan-use-priority-review-voucher</loc>
  <lastmod>2014-07-30T12:06:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2014-financial-and-operating</loc>
  <lastmod>2014-08-05T02:30:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-eu-approval-treatment</loc>
  <lastmod>2014-08-10T22:33:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2014-investor-conference-1</loc>
  <lastmod>2014-08-19T05:30:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-results-four-phase-3-alirocumab</loc>
  <lastmod>2014-08-24T21:03:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-presentation-detailed-positive</loc>
  <lastmod>2014-08-30T23:03:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-submission-application-eylear-aflibercept</loc>
  <lastmod>2014-09-03T23:03:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-breakthrough-therapy</loc>
  <lastmod>2014-09-16T06:38:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-eylear-aflibercept-injection-approved</loc>
  <lastmod>2014-09-21T22:33:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-phase-2-top-line</loc>
  <lastmod>2014-09-29T21:03:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-approval-macular-edema</loc>
  <lastmod>2014-10-06T13:00:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2014-financial-and-operating</loc>
  <lastmod>2014-10-15T12:05:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-genetics-center-fully-operational-announces-new</loc>
  <lastmod>2014-10-16T04:31:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-ranked-number-one-biopharmaceutical-employer-science</loc>
  <lastmod>2014-10-16T10:00:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-demonstrates-significantly-greater</loc>
  <lastmod>2014-10-17T03:00:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-start-phase-3-study-dupilumab</loc>
  <lastmod>2014-10-20T03:01:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2014-investor-conference-2</loc>
  <lastmod>2014-11-03T11:08:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2014-financial-and-operating</loc>
  <lastmod>2014-11-04T01:30:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-results-phase-2b-study-0</loc>
  <lastmod>2014-11-10T20:00:11-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-eylear-aflibercept-injection-approved-0</loc>
  <lastmod>2014-11-17T22:06:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-new-results-six-phase-3-trials</loc>
  <lastmod>2014-11-19T03:15:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-dupilumab-has-received-fda</loc>
  <lastmod>2014-11-19T20:30:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-accepted-priority-review-fda</loc>
  <lastmod>2014-12-01T02:00:58-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/have-you-been-counted-regeneron-and-sanofi-us-join-forces</loc>
  <lastmod>2014-12-15T03:05:06-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-and-panel-discussion-33rd</loc>
  <lastmod>2014-12-19T04:30:38-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-topline-results-first</loc>
  <lastmod>2015-01-08T20:03:16-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2014-financial-and</loc>
  <lastmod>2015-01-09T04:30:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-praluenttm-alirocumab-marketing</loc>
  <lastmod>2015-01-11T20:18:06-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-recommended-approval-treatment-1</loc>
  <lastmod>2015-01-23T02:33:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-praluenttm-alirocumab-biologics</loc>
  <lastmod>2015-01-25T20:18:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2014-financial</loc>
  <lastmod>2015-02-10T01:33:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2015-investor-conference</loc>
  <lastmod>2015-02-13T04:30:28-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-results-cholesterol-counts-show-most-americans-polled-do-not</loc>
  <lastmod>2015-02-18T03:04:04-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/nih-sponsored-comparative-effectiveness-trial-diabetic-macular</loc>
  <lastmod>2015-02-18T12:00:53-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-eu-approval-treatment-0</loc>
  <lastmod>2015-02-26T03:42:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-18-month-results-odyssey-long-term</loc>
  <lastmod>2015-03-15T07:00:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-approval-treatment-0</loc>
  <lastmod>2015-03-25T07:06:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2015-financial-and-operating</loc>
  <lastmod>2015-04-10T05:30:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2015-investor-conference-0</loc>
  <lastmod>2015-04-29T05:33:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2015-financial-and-operating</loc>
  <lastmod>2015-05-07T02:30:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-pivotal-phase-2b</loc>
  <lastmod>2018-12-13T12:38:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/trading-regeneron-common-stock-halted-0</loc>
  <lastmod>2015-06-09T03:05:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-advisory-committee-recommends-approval-regeneron-and-sanofis</loc>
  <lastmod>2015-06-09T14:30:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2015-winners-regeneron-prize-creative</loc>
  <lastmod>2015-06-25T04:31:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-approval-japan-treatment</loc>
  <lastmod>2015-06-25T23:00:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-rapid-response-platform-emerging-infectious-diseases</loc>
  <lastmod>2015-06-29T11:00:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-film-documents-heart-felt-stories-people-living-high-ldl</loc>
  <lastmod>2015-06-30T06:38:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2015-financial-and-operating</loc>
  <lastmod>2015-07-08T05:30:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-phase-3-results-showing-ldl-c</loc>
  <lastmod>2015-07-08T18:00:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-topline-results-phase-3</loc>
  <lastmod>2015-07-14T07:34:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-chmp-recommends-european-approval</loc>
  <lastmod>2015-07-24T03:15:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-launch-major-new-immuno-oncology</loc>
  <lastmod>2015-07-27T21:02:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2015-financial-and-operating</loc>
  <lastmod>2015-08-04T02:30:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-fda-approval-praluentr-alirocumab</loc>
  <lastmod>2015-08-21T06:54:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2015-investor-conference-1</loc>
  <lastmod>2015-08-31T05:30:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-new-positive-praluentr-alirocumab</loc>
  <lastmod>2015-09-01T05:07:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-discovery-cause-rare-genetic-bone-disease-detailed</loc>
  <lastmod>2015-09-01T12:28:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-hires-maya-bermingham-executive-director-public-policy</loc>
  <lastmod>2015-09-10T04:51:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-agreement-barda-development-new-antibody</loc>
  <lastmod>2015-09-21T04:00:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-icahn-school-medicine-mount-sinai-announce-new</loc>
  <lastmod>2015-09-24T04:31:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-approval-praluentr-alirocumab</loc>
  <lastmod>2015-09-27T21:00:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-collaboration-mitsubishi-tanabe-pharma</loc>
  <lastmod>2015-10-01T12:05:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2015-financial-and-operating</loc>
  <lastmod>2015-10-08T05:30:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-publication-positive-phase-2b</loc>
  <lastmod>2015-10-08T05:32:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-additional-350-million-investment-and-200</loc>
  <lastmod>2015-10-18T12:30:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-24th-annual-credit-suisse</loc>
  <lastmod>2015-10-23T05:32:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-named-among-top-two-global-biopharmaceutical-employers</loc>
  <lastmod>2015-10-29T09:40:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-eu-approval-eylear-aflibercept-injection</loc>
  <lastmod>2015-10-30T05:02:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2015-financial-and-operating</loc>
  <lastmod>2015-11-04T01:30:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-results-phase-3-praluentr</loc>
  <lastmod>2015-11-05T12:36:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-survey-us-adults-diabetes-reveals-less-half-understand-their</loc>
  <lastmod>2015-11-06T03:11:22-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-results-pivotal-phase-3-study</loc>
  <lastmod>2019-01-21T18:18:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-new-praluentr-alirocumab-injection</loc>
  <lastmod>2015-11-10T13:00:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-celebrates-patient-innovation-and-growth-new-york</loc>
  <lastmod>2015-11-12T08:47:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-18000-patient-odyssey-outcomes</loc>
  <lastmod>2015-11-23T20:00:06-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-unitedhealth-group-selects</loc>
  <lastmod>2015-12-10T20:01:59-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-mourns-passing-dr-alfred-g-gilman-board-member-and</loc>
  <lastmod>2015-12-27T07:01:49-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-34th-annual-jp-morgan</loc>
  <lastmod>2016-01-07T04:30:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-sarilumab-biologics-license</loc>
  <lastmod>2016-01-07T20:01:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2015-financial-and</loc>
  <lastmod>2016-01-26T04:31:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2016-investor-conference</loc>
  <lastmod>2016-02-02T04:31:59-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-publication-positive-phase-2</loc>
  <lastmod>2016-02-02T07:56:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2015-financial</loc>
  <lastmod>2016-02-09T01:31:58-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-joins-human-vaccines-project-improve-global-disease</loc>
  <lastmod>2016-02-09T11:55:25-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2016-investor-conference-0</loc>
  <lastmod>2016-02-29T04:30:05-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-hires-david-weinreich-md-mba-senior-vice-president</loc>
  <lastmod>2016-02-29T11:59:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-genetics-center-publication-new-england-journal</loc>
  <lastmod>2016-03-02T12:00:05-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-humana-provides-exclusive-or</loc>
  <lastmod>2016-03-04T12:40:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-topline-results-phase-3</loc>
  <lastmod>2016-03-10T20:01:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-strongly-disagree-us-jury-verdict-ongoing</loc>
  <lastmod>2016-03-16T08:31:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-topline-results-phase-3-0</loc>
  <lastmod>2016-03-22T21:59:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bayer-jointly-develop-novel-combination-therapy</loc>
  <lastmod>2016-03-24T04:00:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-phase-3-praluentr-alirocumab</loc>
  <lastmod>2016-03-29T16:59:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-dupilumab-topline-results</loc>
  <lastmod>2016-04-01T07:38:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-medimmune-enter-licensing-agreement-development</loc>
  <lastmod>2016-04-04T12:01:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-announce-collaboration</loc>
  <lastmod>2016-04-11T12:05:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-hires-sally-paull-senior-vice-president-human</loc>
  <lastmod>2016-04-11T12:13:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2016-financial-and-operating</loc>
  <lastmod>2016-04-15T05:30:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2016-investor-conference-1</loc>
  <lastmod>2016-04-29T05:29:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-topline-results-phase-23-fasinumab</loc>
  <lastmod>2016-05-02T03:01:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2016-financial-and-operating</loc>
  <lastmod>2016-05-05T02:30:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-genzyme-present-additional-data-pivotal</loc>
  <lastmod>2016-05-10T14:18:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-us-prescribing-information</loc>
  <lastmod>2016-05-24T18:16:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-selected-society-science-public-new-sponsor-science</loc>
  <lastmod>2016-05-26T04:31:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/words-support-public-figures-regeneron-sts-sponsorship</loc>
  <lastmod>2016-05-26T04:33:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-presents-positive-interim-data-phase-2-proof-concept</loc>
  <lastmod>2016-05-31T05:00:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-dupilumab-used-topical</loc>
  <lastmod>2016-06-05T21:02:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-approval-praluentr-alirocumab-0</loc>
  <lastmod>2016-07-04T21:01:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2016-financial-and-operating</loc>
  <lastmod>2016-07-08T05:31:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/award-winning-chef-elizabeth-falkner-reveals-her-struggle-atopic</loc>
  <lastmod>2016-07-12T03:00:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2016-winners-regeneron-prize-creative</loc>
  <lastmod>2016-07-13T04:30:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2016-investor-conference-2</loc>
  <lastmod>2016-07-18T05:31:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-adicet-bio-announce-strategic-collaboration</loc>
  <lastmod>2016-08-02T04:30:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2016-financial-and-operating</loc>
  <lastmod>2016-08-04T02:30:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-agreement-barda-manufacturing-and-testing</loc>
  <lastmod>2019-01-21T18:17:03-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-positive-phase-3-investigational</loc>
  <lastmod>2016-08-28T22:02:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2016-investor-conference-3</loc>
  <lastmod>2016-09-01T05:30:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-election-bonnie-bassler-phd-and-huda-zoghbi</loc>
  <lastmod>2016-09-12T04:31:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-teva-announce-global-collaboration-develop-and</loc>
  <lastmod>2016-09-20T03:01:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-dupilumab-biologics-license</loc>
  <lastmod>2016-09-25T21:02:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-dupixentr-dupilumab-phase</loc>
  <lastmod>2016-09-30T22:02:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-survey-reveals-widespread-and-serious-impact-moderate-severe</loc>
  <lastmod>2016-10-05T04:40:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2016-financial-and-operating</loc>
  <lastmod>2016-10-07T05:32:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-teva-provide-update-fasinumab-clinical-development</loc>
  <lastmod>2019-01-21T18:13:17-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-25th-annual-credit-suisse</loc>
  <lastmod>2016-10-21T05:30:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/science-magazine-once-again-names-regeneron-best-company-work</loc>
  <lastmod>2016-10-27T11:13:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-receive-complete-response-letter-fda</loc>
  <lastmod>2016-10-28T10:47:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-phase-2-study-aflibercept-co-formulated</loc>
  <lastmod>2016-10-31T11:50:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2016-financial-and-operating</loc>
  <lastmod>2016-11-04T02:32:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-data-phase-3-praluentr-alirocumab</loc>
  <lastmod>2016-11-11T04:00:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-results-phase-3-monarch-study</loc>
  <lastmod>2016-11-16T03:00:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-praluentr-alirocumab</loc>
  <lastmod>2016-11-16T21:02:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-ceo-leonard-schleifer-and-cso-george-yancopoulos-named</loc>
  <lastmod>2016-11-21T03:30:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-marketing-authorization</loc>
  <lastmod>2016-12-07T20:02:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-35th-annual-jp-morgan</loc>
  <lastmod>2016-12-22T04:32:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/science-publication-highlights-precision-medicine-approach</loc>
  <lastmod>2016-12-22T09:00:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-genetics-center-and-geisinger-study-finds-life</loc>
  <lastmod>2016-12-22T09:00:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-hires-jay-markowitz-md-senior-vice-president-portfolio</loc>
  <lastmod>2017-01-04T02:00:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-appeal-us-district-court-rulings-ongoing</loc>
  <lastmod>2017-01-05T15:02:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-provide-update-ongoing-patent-litigation</loc>
  <lastmod>2017-01-09T10:51:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-file-notice-appeal-and-motion-stay-suspend</loc>
  <lastmod>2017-01-14T06:05:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/forty-nations-brightest-young-scientists-named-regeneron-science</loc>
  <lastmod>2017-01-24T07:02:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/tony-coles-md-elected-regeneron-board-directors</loc>
  <lastmod>2017-01-31T02:02:05-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-first-approval-kevzaratm-sarilumab</loc>
  <lastmod>2017-01-31T20:02:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2016-financial-and</loc>
  <lastmod>2017-02-07T01:32:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/amgen-inc-v-sanofi-court-order-granted-stay-pending-appeal</loc>
  <lastmod>2017-02-08T11:58:58-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/appeals-court-grants-stay-permanent-injunction-praluentr</loc>
  <lastmod>2019-01-21T18:06:49-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2016-financial</loc>
  <lastmod>2017-02-09T01:32:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-2017-investor-conference</loc>
  <lastmod>2017-02-13T04:30:06-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-new-data-dupixentr-dupilumab</loc>
  <lastmod>2017-02-27T03:30:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-presentation-positive-data-long</loc>
  <lastmod>2019-01-21T18:03:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-new-phase-3-praluentr-alirocumab</loc>
  <lastmod>2017-03-07T03:00:37-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/teen-scientist-researches-new-approach-neurological-damage-wins</loc>
  <lastmod>2017-03-14T17:30:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/uk-biobank-regeneron-and-gsk-announce-largest-gene-sequencing</loc>
  <lastmod>2017-03-22T16:02:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-fda-approval-dupixentr-dupilumab</loc>
  <lastmod>2017-03-28T07:42:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-host-investor-conference-call-discuss</loc>
  <lastmod>2017-03-28T09:52:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-evinacumab-has-received-fda-breakthrough</loc>
  <lastmod>2017-04-06T03:00:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2017-financial-and-operating</loc>
  <lastmod>2017-04-14T05:32:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-receive-positive-chmp-opinion-kevzarar</loc>
  <lastmod>2017-04-23T21:02:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-fda-approval-new-once-monthly</loc>
  <lastmod>2017-04-25T04:00:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-kevzarar-sarilumab-biologics</loc>
  <lastmod>2017-04-27T21:02:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2017-financial-and-operating</loc>
  <lastmod>2017-05-04T02:32:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/survey-results-show-eighty-percent-rheumatoid-arthritis-patients</loc>
  <lastmod>2017-05-04T03:01:50-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-0</loc>
  <lastmod>2017-05-05T05:32:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-inovio-enter-immuno-oncology-clinical-study</loc>
  <lastmod>2017-05-08T03:30:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sillajen-announce-immuno-oncology-clinical-study</loc>
  <lastmod>2017-05-09T05:56:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-1</loc>
  <lastmod>2017-05-18T05:30:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-fda-approval-kevzarar-sarilumab</loc>
  <lastmod>2017-05-22T13:46:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-angptl3evinacumab-publication-new-england</loc>
  <lastmod>2017-05-24T13:00:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-positive-study-results</loc>
  <lastmod>2017-06-04T06:02:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-results-first-dedicated</loc>
  <lastmod>2017-06-11T07:02:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-recognized-civic-50-list-most-community-minded</loc>
  <lastmod>2018-09-10T18:22:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-details-royalty-agreement-novartis-canakinumab-acz885</loc>
  <lastmod>2017-06-22T05:02:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-approval-kevzarar-sarilumab-treat</loc>
  <lastmod>2019-01-21T17:59:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2017-winners-regeneron-prize-creative</loc>
  <lastmod>2017-07-13T04:30:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2017-financial-and-operating</loc>
  <lastmod>2017-07-13T05:30:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-receive-positive-chmp-opinion-dupixentr</loc>
  <lastmod>2017-07-21T03:30:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2017-financial-and-operating</loc>
  <lastmod>2017-08-03T02:30:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/accessing-regeneron-second-quarter-2017-financial-and-operating</loc>
  <lastmod>2017-08-03T04:38:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-discontinue-development-suptavumab-respiratory</loc>
  <lastmod>2017-08-14T05:08:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-new-analyses-praluentr-alirocumab</loc>
  <lastmod>2017-08-25T04:02:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-2</loc>
  <lastmod>2017-08-31T12:02:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-cemiplimab-regn2810-has-received</loc>
  <lastmod>2017-09-07T21:00:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-study-results-dupixentr</loc>
  <lastmod>2017-09-15T22:16:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/important-note-regarding-september-11-2017-press-release</loc>
  <lastmod>2018-09-10T18:19:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-dupilumab-topline-0</loc>
  <lastmod>2019-01-21T17:51:09-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-approval-dupixentr-dupilumab-treat</loc>
  <lastmod>2019-01-21T17:45:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-new-collaborations-hhs-develop-antibodies</loc>
  <lastmod>2017-10-02T03:00:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/appellate-court-orders-new-trial-and-vacates-permanent</loc>
  <lastmod>2017-10-06T08:39:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/internationally-acclaimed-writer-and-executive-producer-hbos</loc>
  <lastmod>2017-10-11T04:00:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2017-financial-and-operating</loc>
  <lastmod>2017-10-11T05:32:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-phase-2-study-results</loc>
  <lastmod>2017-10-16T04:00:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/science-magazine-ranks-regeneron-1-biopharma-employer-fifth-time</loc>
  <lastmod>2017-10-19T10:32:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-300-additional-jobs-limerick</loc>
  <lastmod>2018-07-10T06:05:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-first-global-day-service-supports-over-100-non-profit</loc>
  <lastmod>2017-10-27T03:00:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupilumab-significantly-reduced-steroid-use-asthma-attacks-and</loc>
  <lastmod>2019-01-21T17:40:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-share-clinical-progress-regn1979-and-cemiplimab</loc>
  <lastmod>2017-11-01T05:02:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-new-analyses-praluentr-alirocumab-0</loc>
  <lastmod>2017-11-07T03:01:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2017-financial-and-operating</loc>
  <lastmod>2017-11-08T01:32:03-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentation</loc>
  <lastmod>2017-11-15T04:32:00-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-eylear-aflibercept-injection-and</loc>
  <lastmod>2017-11-26T21:02:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-decibel-therapeutics-announce-strategic</loc>
  <lastmod>2017-11-29T02:00:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-acceptance-sbla-filing-12-week-dosing</loc>
  <lastmod>2017-12-11T02:00:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-topline-pivotal-results</loc>
  <lastmod>2019-01-21T17:36:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-collaboration-programs-highlighted-during-sanofi</loc>
  <lastmod>2017-12-12T20:32:00-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-isa-pharmaceuticals-announce-strategic-immuno</loc>
  <lastmod>2017-12-17T20:00:06-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-36th-annual-jp-morgan</loc>
  <lastmod>2017-12-27T04:32:00-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-forms-consortium-leading-life-sciences-companies</loc>
  <lastmod>2018-01-08T02:00:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-accelerate-and-expand-investment-cemiplimab</loc>
  <lastmod>2019-01-21T17:31:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-approval-dupixentr-dupilumab-japan-treatment</loc>
  <lastmod>2018-01-22T02:00:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/forty-nations-most-promising-young-scientists-named-finalists</loc>
  <lastmod>2018-01-23T07:09:23-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2017-financial-and</loc>
  <lastmod>2018-01-23T11:06:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2017-financial</loc>
  <lastmod>2018-02-08T01:32:50-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-appointment-marion-mccourt-senior-vice</loc>
  <lastmod>2018-02-12T02:00:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-review-dupixentr-dupilumab-potential-treatment-moderate</loc>
  <lastmod>2018-03-01T20:04:25-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-plans-make-praluentr-alirocumab</loc>
  <lastmod>2018-03-10T04:02:11-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/praluentr-alirocumab-injection-significantly-reduced-risk</loc>
  <lastmod>2018-03-10T04:36:00-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/teen-scientists-win-18-million-regeneron-science-talent-search</loc>
  <lastmod>2018-03-13T17:30:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-demonstrates-positive-topline</loc>
  <lastmod>2018-03-19T03:00:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-genetics-centerr-publication-new-england-journal</loc>
  <lastmod>2018-03-21T13:06:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-alnylam-pharmaceuticals-announce-collaboration</loc>
  <lastmod>2018-03-21T13:06:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/ema-review-cemiplimab-potential-treatment-advanced-cutaneous</loc>
  <lastmod>2018-04-02T21:02:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/ema-review-dupixentr-dupilumab-potential-treatment-inadequately</loc>
  <lastmod>2018-04-02T21:02:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2018-financial-and-operating</loc>
  <lastmod>2018-04-09T05:32:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-3</loc>
  <lastmod>2018-04-23T05:30:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-conduct-priority-review-cemiplimab-potential-treatment</loc>
  <lastmod>2018-04-29T23:25:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-lower-net-price-praluentr-alirocumab</loc>
  <lastmod>2018-05-01T03:00:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2018-financial-and-operating</loc>
  <lastmod>2018-05-03T02:32:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-phase-3-trial-dupixentr-dupilumab-adolescents</loc>
  <lastmod>2018-05-16T05:38:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-share-first-positive-clinical-data</loc>
  <lastmod>2018-05-16T13:00:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentation-0</loc>
  <lastmod>2018-05-18T05:30:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-two-positive-phase-3</loc>
  <lastmod>2018-05-21T10:16:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-investigational-ebola-treatment-shipping-democratic</loc>
  <lastmod>2018-05-31T12:06:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-pivotal-cemiplimab-trials</loc>
  <lastmod>2018-06-04T10:16:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-zoetis-announce-collaboration-research-antibody</loc>
  <lastmod>2018-06-06T03:00:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2018-financial-and-operating</loc>
  <lastmod>2018-07-09T05:30:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2018-financial-and-operating</loc>
  <lastmod>2018-08-02T02:33:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2018-winners-regeneron-prize-creative</loc>
  <lastmod>2018-08-03T03:32:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-bluebird-bio-announce-collaboration-discover</loc>
  <lastmod>2018-08-06T02:32:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-regulatory-update-eylear-aflibercept</loc>
  <lastmod>2018-08-13T03:00:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-teva-announce-positive-topline-phase-3-fasinumab</loc>
  <lastmod>2018-08-16T03:00:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-sbla-wet-age-related</loc>
  <lastmod>2018-08-17T03:00:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentation-1</loc>
  <lastmod>2018-08-24T05:30:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-review-supplemental-biologics-license-application-praluentr</loc>
  <lastmod>2019-01-17T18:58:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-review-eylea-aflibercept-injection-treatment-diabetic</loc>
  <lastmod>2018-09-13T08:24:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-phase-3-results-presented-dupixentr-dupilumab-show</loc>
  <lastmod>2018-09-15T02:20:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-libtayor-cemiplimab-rwlc-first-and-only-treatment</loc>
  <lastmod>2018-09-28T16:40:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2018-financial-and-operating</loc>
  <lastmod>2018-10-08T09:33:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-rwlc-data-esmo-2018-congress-provide-new</loc>
  <lastmod>2018-10-08T18:09:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-showed-positive-topline-results-two-phase-3</loc>
  <lastmod>2018-10-16T01:02:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/kevzarar-sarilumab-data-2018-acrarhp-annual-meeting-provide</loc>
  <lastmod>2018-10-19T07:03:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-asthma-indication-dupixentr-dupilumab</loc>
  <lastmod>2018-10-19T17:58:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-improves-diabetic-retinopathy-and</loc>
  <lastmod>2018-10-25T07:03:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-ranked-1-biopharma-employer-sixth-time-science</loc>
  <lastmod>2018-10-26T07:02:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-grants-priority-review-dupixentr-dupilumab-potential</loc>
  <lastmod>2018-11-06T01:01:06-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2018-financial-and-operating</loc>
  <lastmod>2018-11-06T06:33:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-detailed-results</loc>
  <lastmod>2018-11-07T17:19:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/odyssey-outcomes-investigators-highlight-aha-praluentr</loc>
  <lastmod>2018-11-11T08:16:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentation-2</loc>
  <lastmod>2018-11-20T17:03:52-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-presents-positive-data-ash-regn1979-cd20xcd3</loc>
  <lastmod>2018-12-01T12:02:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-37th-annual-jp-morgan</loc>
  <lastmod>2018-12-18T16:04:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-restructure-immuno-oncology-collaboration</loc>
  <lastmod>2019-01-07T02:32:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-commercial-and-pipeline-progress-jp</loc>
  <lastmod>2019-01-07T07:06:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2018-financial-and</loc>
  <lastmod>2019-01-18T16:04:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/forty-nations-most-brilliant-young-scientists-named-finalists</loc>
  <lastmod>2019-01-23T12:05:11-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/chmp-recommends-approval-praluentr-alirocumab-injection-reduce</loc>
  <lastmod>2019-02-04T16:26:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2018-financial</loc>
  <lastmod>2019-02-06T06:33:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/one-year-results-positive-phase-3-eylea-trial-diabetic</loc>
  <lastmod>2019-02-09T16:32:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-offer-praluentr-alirocumab-new-reduced-us</loc>
  <lastmod>2019-02-11T07:01:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentation-3</loc>
  <lastmod>2019-02-14T09:32:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/us-and-eu-patent-office-decisions-invalidate-amgen-subsidiary</loc>
  <lastmod>2019-02-15T16:43:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-results-presented-two-phase-3-trials-dupixentr</loc>
  <lastmod>2019-02-25T12:45:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-strongly-disagree-verdict-upholding-three</loc>
  <lastmod>2019-02-25T17:25:04-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-analyses-be-presented-aad-dupixentr-dupilumab-and-burden</loc>
  <lastmod>2019-03-01T07:00:58-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/chmp-recommends-approval-dupixentr-dupilumab-asthma-indication</loc>
  <lastmod>2019-03-01T08:37:03-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-undertake-priority-review-dupixentr-dupilumab-adults</loc>
  <lastmod>2019-03-08T01:00:17-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-call</loc>
  <lastmod>2019-03-08T16:03:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-genetic-data-regeneron-and-gsk-50000-uk-biobank-participants</loc>
  <lastmod>2019-03-11T01:01:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-dupixentr-dupilumab-moderate-severe-atopic</loc>
  <lastmod>2019-03-11T15:46:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/teen-scientists-win-18-million-regeneron-science-talent-search-0</loc>
  <lastmod>2019-03-12T22:00:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-present-new-praluentr-alirocumab-data-acc19</loc>
  <lastmod>2019-03-13T07:05:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/praluentr-alirocumab-now-approved-european-union-reduce-risk</loc>
  <lastmod>2019-03-15T16:04:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-alnylam-announce-broad-collaboration-discover</loc>
  <lastmod>2019-04-08T07:03:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2019-financial-and-operating</loc>
  <lastmod>2019-04-08T16:03:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/chmp-issues-positive-opinion-libtayor-cemiplimab-advanced</loc>
  <lastmod>2019-04-26T11:16:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-praluentr-alirocumab-prevent-heart-attack-stroke</loc>
  <lastmod>2019-04-26T19:20:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-4</loc>
  <lastmod>2019-05-07T17:45:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2019-financial-and-operating-0</loc>
  <lastmod>2019-05-07T21:48:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-severe-asthma-european-commission</loc>
  <lastmod>2019-05-07T08:59:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-diabetic-retinopathy</loc>
  <lastmod>2019-05-13T14:45:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/updated-libtayor-cemiplimab-rwlc-results-reinforce-durable-and</loc>
  <lastmod>2019-05-16T07:00:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentation-4</loc>
  <lastmod>2019-05-23T09:30:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-cd20xcd3-bispecific-regn1979-shows-positive-results</loc>
  <lastmod>2019-06-14T07:30:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-topline-phase-2-results</loc>
  <lastmod>2019-06-21T00:59:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-dupixentr-dupilumab-chronic-rhinosinusitis-nasal</loc>
  <lastmod>2019-06-26T13:29:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/chmp-recommends-approval-dupixentr-dupilumab-moderate-severe</loc>
  <lastmod>2019-06-28T06:59:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-advanced-cutaneous-squamous-cell</loc>
  <lastmod>2019-07-01T10:00:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2019-financial-and-operating</loc>
  <lastmod>2019-07-08T09:30:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2019-winners-regeneron-prize-creative</loc>
  <lastmod>2019-07-18T07:30:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-european-commission-adolescents</loc>
  <lastmod>2019-08-06T00:59:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-showed-positive-topline-results-phase-3</loc>
  <lastmod>2019-08-06T01:04:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2019-financial-and-operating</loc>
  <lastmod>2019-08-06T06:31:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/palm-ebola-clinical-trial-stopped-early-regenerons-regn-eb3</loc>
  <lastmod>2019-08-12T10:02:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-prefilled-syringe</loc>
  <lastmod>2019-08-13T07:00:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-topline-results-phase-3-trial</loc>
  <lastmod>2019-08-14T07:00:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentation-5</loc>
  <lastmod>2019-08-15T09:30:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/us-district-court-invalidates-amgen-patent-claims-targeting</loc>
  <lastmod>2019-08-28T16:58:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-debuts-prestigious-dow-jones-sustainability-world</loc>
  <lastmod>2019-09-17T07:00:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/educational-campaign-helps-teens-and-their-caregivers-tackle</loc>
  <lastmod>2019-09-18T06:59:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/chmp-recommends-approval-dupixentr-dupilumab-severe-chronic</loc>
  <lastmod>2019-09-20T06:44:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/lancet-publishes-results-two-positive-phase-3-trials-dupixentr</loc>
  <lastmod>2019-09-20T06:59:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2019-financial-and-operating</loc>
  <lastmod>2019-10-10T09:30:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-5</loc>
  <lastmod>2019-10-18T08:30:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-colleagues-support-150-community-organizations-during</loc>
  <lastmod>2019-10-25T07:00:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-ranked-2-science-magazines-top-biopharma-companies</loc>
  <lastmod>2019-10-25T07:05:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-now-approved-european-union-severe-chronic</loc>
  <lastmod>2019-10-29T08:15:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2019-financial-and-operating</loc>
  <lastmod>2019-11-05T06:30:56-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-updates-phase-3-libtayor-cemiplimab</loc>
  <lastmod>2019-11-05T06:40:51-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-vyriad-announce-strategic-agreement-discovery-and</loc>
  <lastmod>2019-11-06T07:01:00-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-results-cd20xcd3-and-bcmaxcd3-bispecifics-and</loc>
  <lastmod>2019-11-06T09:01:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-6</loc>
  <lastmod>2019-11-12T07:30:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-yancopoulos-receives-columbia-colleges-alexander</loc>
  <lastmod>2019-11-22T07:01:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-results-ebola-clinical</loc>
  <lastmod>2019-11-27T17:00:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-topline-phase-2-data-anti-c5</loc>
  <lastmod>2019-12-06T15:14:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/first-clinical-data-regn5458-bcmaxcd3-show-positive-preliminary</loc>
  <lastmod>2019-12-08T09:00:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-intent-restructure-antibody</loc>
  <lastmod>2019-12-10T08:29:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-cold-spring-harbor-laboratory-unveil-new-dedicated</loc>
  <lastmod>2019-12-12T07:00:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/society-science-public-announces-regeneron-new-title-sponsor</loc>
  <lastmod>2019-12-12T10:15:37-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-38th-annual-jp-morgan</loc>
  <lastmod>2019-12-20T07:00:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/publication-highlights-regenerons-costimulatory-bispecific</loc>
  <lastmod>2020-01-08T14:03:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-garetosmab-phase-2-results</loc>
  <lastmod>2020-01-10T12:48:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2019-financial-and</loc>
  <lastmod>2020-01-10T07:00:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/forty-nations-brightest-young-scientists-named-finalists</loc>
  <lastmod>2020-01-22T12:01:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-priority-review-dupixentr-dupilumab-children-aged-6</loc>
  <lastmod>2020-01-28T00:59:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody</loc>
  <lastmod>2020-03-04T14:25:09-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2019-financial</loc>
  <lastmod>2020-02-06T06:30:54-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-reduced-risk-developing-vision</loc>
  <lastmod>2020-02-10T17:19:59-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-7</loc>
  <lastmod>2020-02-12T16:01:54-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-8</loc>
  <lastmod>2020-03-03T16:06:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical</loc>
  <lastmod>2020-03-16T09:36:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody</loc>
  <lastmod>2020-03-17T07:00:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/first-patient-outside-us-treated-global-kevzarar-sarilumab</loc>
  <lastmod>2020-03-30T07:03:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-american-college-cardiology-presentation</loc>
  <lastmod>2020-03-30T11:46:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-phase-3-data-revolutionizing-atopic</loc>
  <lastmod>2020-04-03T00:59:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-finalizes-praluentr-alirocumab-restructuring-and</loc>
  <lastmod>2020-04-06T17:00:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-zai-lab-announce-regional-strategic-collaboration</loc>
  <lastmod>2020-04-08T10:06:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-priority-review-biologics-license-application-regn</loc>
  <lastmod>2020-04-16T08:55:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive</loc>
  <lastmod>2020-04-27T11:06:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-libtayor-cemiplimab-monotherapy-first-line</loc>
  <lastmod>2020-04-27T06:59:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-9</loc>
  <lastmod>2020-04-29T07:00:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-shows-clinically-meaningful-and-durable</loc>
  <lastmod>2020-05-05T00:59:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2020-financial-and-operating</loc>
  <lastmod>2020-05-05T06:31:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-colorado-center-personalized-medicine-announce</loc>
  <lastmod>2020-05-11T07:01:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-presentations-asco-2020-showcase-diverse-clinical</loc>
  <lastmod>2020-05-14T07:15:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-eosinophilic-esophagitis-trial-meets-both-co</loc>
  <lastmod>2020-05-22T18:48:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-secondary-offering-its-common-stock-held</loc>
  <lastmod>2020-05-25T12:40:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-dupixentr-dupilumab-first-biologic-medicine</loc>
  <lastmod>2020-05-26T11:39:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-pricing-secondary-offering-its-common-stock</loc>
  <lastmod>2020-05-26T19:55:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-rwlc-longer-term-results-advanced-cutaneous</loc>
  <lastmod>2020-05-29T08:01:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-completes-secondary-offering-common-stock-held-sanofi</loc>
  <lastmod>2020-05-29T16:01:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop</loc>
  <lastmod>2020-06-01T07:01:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-10</loc>
  <lastmod>2020-06-05T07:00:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-virtual-only-format-2020-annual-meeting</loc>
  <lastmod>2020-06-08T09:01:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-recognized-healthcare-sector-leader-civic-50-list-most</loc>
  <lastmod>2020-06-10T09:02:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-collaborations-dupixentr-dupilumab-highlighted-during</loc>
  <lastmod>2020-06-11T00:59:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-begins-first-clinical-trials-anti-viral-antibody</loc>
  <lastmod>2020-06-11T07:53:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/two-science-publications-highlight-potential-regn-cov2-anti</loc>
  <lastmod>2020-07-02T11:12:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-china-adults-moderate-severe-atopic</loc>
  <lastmod>2020-06-19T07:30:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-new-dupixentr-dupilumab-pre-filled-pen-designed</loc>
  <lastmod>2020-06-19T13:44:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2020-winners-regeneron-prize-creative</loc>
  <lastmod>2020-06-22T07:01:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-publication-highlights-preclinical-research-showing</loc>
  <lastmod>2020-06-24T14:00:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-vigorously-defend-allegations-related-contributions</loc>
  <lastmod>2020-06-24T15:23:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3</loc>
  <lastmod>2020-07-02T16:29:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention</loc>
  <lastmod>2020-07-06T07:01:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-manufacturing-and-supply-agreement-barda-and</loc>
  <lastmod>2020-07-07T07:01:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2020-financial-and-operating</loc>
  <lastmod>2020-07-08T16:30:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/barda-procures-regenerons-regn-eb3-investigational-ebola</loc>
  <lastmod>2020-07-29T07:01:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/teen-scientists-win-18-million-virtual-regeneron-science-talent</loc>
  <lastmod>2020-07-29T21:00:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2020-financial-and-operating</loc>
  <lastmod>2020-08-05T06:31:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-pricing-public-offering-senior-unsecured</loc>
  <lastmod>2020-08-07T16:05:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-evinacumab-biologics-license-application-priority</loc>
  <lastmod>2020-08-12T07:01:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-roche-collaborate-significantly-increase-global</loc>
  <lastmod>2020-08-19T01:00:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-phase-3</loc>
  <lastmod>2020-08-19T20:26:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations</loc>
  <lastmod>2020-08-26T07:01:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-400-new-jobs-limerick</loc>
  <lastmod>2020-08-27T09:25:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/late-breaking-libtayor-cemiplimab-pivotal-data-advanced-non</loc>
  <lastmod>2020-09-03T07:12:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-long-term-data-show-sustained-improvement</loc>
  <lastmod>2020-09-08T00:59:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-grants-dupixentr-dupilumab-breakthrough-therapy-designation</loc>
  <lastmod>2020-09-14T00:59:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/recovery-covid-19-phase-3-trial-evaluate-regenerons-regn-cov2</loc>
  <lastmod>2020-09-21T09:02:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-pivotal-data-libtayor-cemiplimab-monotherapy-locally</loc>
  <lastmod>2020-09-18T03:06:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/late-breaking-esmo-presentation-shows-libtayor-cemiplimab</loc>
  <lastmod>2020-09-21T08:25:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and</loc>
  <lastmod>2020-09-29T16:01:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2020-financial-and-operating</loc>
  <lastmod>2020-10-06T16:05:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-significantly-reduced-severe-asthma-attacks</loc>
  <lastmod>2020-10-13T00:59:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-antibody-cocktail-regn-eb3-inmazebr-first-fda</loc>
  <lastmod>2020-10-14T19:27:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/chmp-recommends-approval-dupixentr-dupilumab-children-aged-6-11</loc>
  <lastmod>2020-10-16T07:59:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-late-breaking-pivotal-data-showing</loc>
  <lastmod>2020-10-26T07:59:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-0</loc>
  <lastmod>2020-10-27T16:30:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates</loc>
  <lastmod>2020-10-28T17:01:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-efficacy-and-safety-patients-young-six-years</loc>
  <lastmod>2020-10-29T02:00:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-priority-review-libtayor-cemiplimab-rwlc-advanced</loc>
  <lastmod>2020-10-29T07:02:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-once-again-earns-1-ranking-science-magazines-top</loc>
  <lastmod>2020-10-29T14:33:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regn-cov2-independent-data-monitoring-committee-recommends</loc>
  <lastmod>2020-10-30T09:13:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2020-financial-and-operating</loc>
  <lastmod>2020-11-05T06:32:05-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/recovery-trial-data-monitoring-committee-recommends-continuing</loc>
  <lastmod>2020-11-05T15:22:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-1</loc>
  <lastmod>2020-11-13T16:15:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-included-dow-jones-sustainability-world-index-second</loc>
  <lastmod>2020-11-16T07:01:25-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive</loc>
  <lastmod>2020-11-22T20:40:16-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-european-commission-first-and-only</loc>
  <lastmod>2020-11-30T00:59:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-webcast-american-society-hematology</loc>
  <lastmod>2020-11-30T07:01:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regenerons-bcmaxcd3-bispecific-antibody-regn5458-shows-deep-and</loc>
  <lastmod>2020-12-05T17:00:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-39th-annual-jp-morgan</loc>
  <lastmod>2020-12-16T07:02:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-initial</loc>
  <lastmod>2020-12-17T17:22:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-initial-data-covid-19-antibody</loc>
  <lastmod>2020-12-29T16:30:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-us-government-agreement-purchase-additional</loc>
  <lastmod>2021-01-12T17:45:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2020-financial-and</loc>
  <lastmod>2021-01-19T16:15:54-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/forty-nations-most-talented-young-scientists-named-finalists</loc>
  <lastmod>2021-01-21T12:43:52-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-positive-interim-data-regen-covtm-antibody</loc>
  <lastmod>2021-01-26T07:02:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regen-covtm-antibody-cocktail-active-against-sars-cov-2-variants</loc>
  <lastmod>2021-01-27T11:53:28-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-dupixentr-dupilumab-data-showcasing-improvements-across-four</loc>
  <lastmod>2021-02-01T09:59:47-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2020-financial</loc>
  <lastmod>2021-02-05T06:31:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-libtayor-cemiplimab-rwlc-first-immunotherapy</loc>
  <lastmod>2021-02-09T17:24:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-first-class-evkeezatm-evinacumab-dgnb-patients</loc>
  <lastmod>2021-02-11T14:01:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/us-federal-circuit-court-appeals-rules-favor-regeneron-and</loc>
  <lastmod>2021-02-11T17:06:41-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/lancet-publishes-libtayor-cemiplimab-data-showing-extended</loc>
  <lastmod>2021-02-12T01:01:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-2</loc>
  <lastmod>2021-02-12T16:16:26-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-libtayor-cemiplimab-rwlc-monotherapy-patients-first</loc>
  <lastmod>2021-02-22T13:01:23-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/independent-data-monitoring-committee-finds-clear-efficacy-regen</loc>
  <lastmod>2021-02-25T07:04:50-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/ema-issues-advice-regenerons-antibody-cocktail-casirivimab</loc>
  <lastmod>2021-02-26T06:48:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-phase-2-data-evaluating-fel-d-1</loc>
  <lastmod>2021-02-27T18:26:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-dupixentr-dupilumab-review-children-moderate-severe</loc>
  <lastmod>2021-03-04T01:00:11-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-libtayor-cemiplimab-monotherapy-advanced-cervical</loc>
  <lastmod>2021-03-15T02:01:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/teen-scientists-win-18-million-virtual-regeneron-science-0</loc>
  <lastmod>2021-03-17T20:58:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-shows-regen-covtm-casirivimab-imdevimab-antibody</loc>
  <lastmod>2021-03-23T02:01:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/nih-sponsored-trial-finds-eylear-aflibercept-injection-reduced</loc>
  <lastmod>2021-03-30T19:06:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2021-financial-and-operating</loc>
  <lastmod>2021-04-06T16:07:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/nih-covid-19-treatment-guidelines-strongly-recommend-use-regen</loc>
  <lastmod>2021-04-09T08:16:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars</loc>
  <lastmod>2021-04-12T01:01:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-treatment-trial-recently-infected-asymptomatic-patients</loc>
  <lastmod>2021-04-12T01:16:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-dupixentr-dupilumab-analyses-two-upcoming-dermatology</loc>
  <lastmod>2021-04-23T09:59:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-3</loc>
  <lastmod>2021-04-23T16:06:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/ats-2021-breaking-news-session-feature-pivotal-data-regen-covtm</loc>
  <lastmod>2021-05-03T08:05:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2021-financial-and-operating</loc>
  <lastmod>2021-05-06T06:32:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-phase-3-libtayor-cemiplimab-results-advanced-cervical</loc>
  <lastmod>2021-05-12T13:31:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/pivotal-data-ats-2021-show-dupixentr-dupilumab-significantly</loc>
  <lastmod>2021-05-17T09:59:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-data-presented-ats-2021-show-regen-covtm-casirivimab</loc>
  <lastmod>2021-05-17T10:01:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-rwlc-presentations-asco-highlight-expanding</loc>
  <lastmod>2021-05-19T17:02:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/teen-scientists-and-engineers-win-5-million-largest-global-high</loc>
  <lastmod>2021-05-21T11:45:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-receives-positive-chmp-opinion-treatment</loc>
  <lastmod>2021-05-24T01:02:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-4</loc>
  <lastmod>2021-05-25T16:16:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-authorizes-lower-1200-mg-intravenous-and-subcutaneous-dose</loc>
  <lastmod>2021-06-04T07:01:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regen-covtm-casirivimab-and-imdevimab-phase-3-recovery-trial</loc>
  <lastmod>2021-08-25T09:00:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-participate-guggenheim-biopharma-strategy-series</loc>
  <lastmod>2021-06-22T16:15:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-european-commission-first-line</loc>
  <lastmod>2021-06-25T01:00:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-european-commission-first</loc>
  <lastmod>2021-06-25T01:15:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/intellia-and-regeneron-announce-landmark-clinical-data-showing</loc>
  <lastmod>2021-06-26T11:16:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-smpc-updated-long-term-data-reinforcing-well</loc>
  <lastmod>2021-06-28T00:59:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-genetics-center-discovers-gpr75-gene-mutations-protect</loc>
  <lastmod>2021-07-01T14:05:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2021-financial-and-operating</loc>
  <lastmod>2021-07-07T16:16:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/japan-becomes-first-country-approve-regeneron-antibody-cocktail</loc>
  <lastmod>2021-07-20T01:00:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-astrazeneca-research-develop-and-commercialize-new</loc>
  <lastmod>2021-07-27T07:02:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-significantly-improved-itch-and-hives</loc>
  <lastmod>2021-07-29T13:55:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-expands-authorized-use-regen-covtm-casirivimab-and-imdevimab</loc>
  <lastmod>2021-07-30T13:45:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2021-winners-regeneron-prize-creative</loc>
  <lastmod>2021-08-03T07:05:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-phase-3-trial</loc>
  <lastmod>2021-08-04T17:06:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/phase-3-trial-libtayor-cemiplimab-rwlc-combined-chemotherapy</loc>
  <lastmod>2021-08-26T12:00:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2021-financial-and-operating</loc>
  <lastmod>2021-08-05T07:20:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/uk-authorizes-regeneron-antibody-cocktail-prevent-and-treat</loc>
  <lastmod>2021-08-20T07:01:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-topline-phase-2-data-high-dose</loc>
  <lastmod>2021-08-24T07:01:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-pivotal-trial-meets-all-primary-and</loc>
  <lastmod>2021-08-30T00:59:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-5</loc>
  <lastmod>2021-09-08T16:07:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-new-us-government-agreement-purchase</loc>
  <lastmod>2021-09-14T20:06:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/esmo-late-breaking-data-show-libtayor-cemiplimab-and</loc>
  <lastmod>2021-09-19T11:30:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-dupixentr-dupilumab-data-patients-young-six-years-old</loc>
  <lastmod>2021-09-21T00:59:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-libtayor-cemiplimab-rwlc-priority-review-advanced</loc>
  <lastmod>2021-09-28T07:03:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-phase-3-trial-0</loc>
  <lastmod>2021-09-29T17:01:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-regen-covtm-casirivimab-and-imdevimab-data-show-supportive</loc>
  <lastmod>2021-09-30T01:02:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2021-financial-and-operating</loc>
  <lastmod>2021-10-11T16:16:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-review</loc>
  <lastmod>2021-10-14T07:22:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-expands-approval-dupixentr-dupilumab-include-children-aged-6</loc>
  <lastmod>2021-10-20T17:30:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-first-biologic-significantly-reduce-itch-and</loc>
  <lastmod>2021-10-22T00:59:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/second-dupixentr-dupilumab-phase-3-eosinophilic-esophagitis</loc>
  <lastmod>2021-10-25T01:00:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2021-financial-and-operating</loc>
  <lastmod>2021-11-04T06:32:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-presentations-ash-highlight-expanding-clinical</loc>
  <lastmod>2021-11-04T10:00:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-phase-3-analyses-show-single-dose-regen-covr-casirivimab-and</loc>
  <lastmod>2021-11-08T07:04:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/chmp-recommends-eu-approval-regeneron-antibody-cocktail-treat</loc>
  <lastmod>2021-11-11T11:03:58-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-antibody-cocktail-approved-european-commission-treat</loc>
  <lastmod>2021-11-12T10:20:49-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-3-billion-share-repurchase-program</loc>
  <lastmod>2021-11-12T16:12:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-listed-dow-jones-sustainability-world-index-third</loc>
  <lastmod>2021-11-15T07:05:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-6</loc>
  <lastmod>2021-11-16T16:16:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-participate-hc-wainwright-co-virtual-event</loc>
  <lastmod>2021-12-03T10:00:58-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-phase-3-0</loc>
  <lastmod>2021-12-08T17:30:28-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/new-regn5458-bcmaxcd3-phase-1-data-show-75-response-rate-highest</loc>
  <lastmod>2021-12-13T08:39:09-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-phase-3-dupixentr-dupilumab-data-children-6-months-5</loc>
  <lastmod>2021-12-13T00:59:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-40th-annual-jp-morgan</loc>
  <lastmod>2021-12-22T16:16:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-ultragenyx-collaborate-commercialize-evkeezar</loc>
  <lastmod>2022-01-07T07:02:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2021-financial-and</loc>
  <lastmod>2022-01-13T16:06:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/second-positive-phase-3-dupixentr-dupilumab-trial-confirms</loc>
  <lastmod>2022-01-19T00:59:52-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-review-libtayor-cemiplimab-rwlc-combination</loc>
  <lastmod>2022-01-19T07:02:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/forty-accomplished-young-scientists-named-finalists-2022</loc>
  <lastmod>2022-01-20T12:00:54-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-regulatory-update-libtayor</loc>
  <lastmod>2022-01-28T07:02:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/chmp-recommends-approval-dupixentr-dupilumab-children-aged-6-0</loc>
  <lastmod>2022-01-31T01:00:17-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-dupixentr-dupilumab-data-across-five-diseases</loc>
  <lastmod>2022-02-01T16:30:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2021-financial</loc>
  <lastmod>2022-02-04T06:31:17-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-dupixentr-dupilumab-priority-review-children-aged-6</loc>
  <lastmod>2022-02-10T01:00:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-presents-encouraging-phase-2-results-high-dose</loc>
  <lastmod>2022-02-11T07:50:59-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-7</loc>
  <lastmod>2022-02-17T16:10:04-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-ongoing-dupixentr-dupilumab</loc>
  <lastmod>2022-02-18T01:00:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/late-breaking-phase-3-data-2022-aaaai-annual-meeting-show</loc>
  <lastmod>2022-02-26T12:00:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/late-breaking-data-2022-aaaai-annual-meeting-show-dupixentr</loc>
  <lastmod>2022-02-26T12:05:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/intellia-and-regeneron-announce-updated-phase-1-data</loc>
  <lastmod>2022-02-28T16:05:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/students-win-18-million-regeneron-science-talent-search-2022</loc>
  <lastmod>2022-03-15T21:19:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/late-breaking-phase-3-data-aad-2022-show-dupixentr-dupilumab</loc>
  <lastmod>2022-03-26T10:00:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-dupixentr-dupilumab-priority-review-patients-aged-12</loc>
  <lastmod>2022-04-04T01:00:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2022-financial-and-operating</loc>
  <lastmod>2022-04-05T16:07:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-european-commission-children-aged-6</loc>
  <lastmod>2022-04-07T01:00:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/us-fda-extends-review-biologics-license-application-regen-covr</loc>
  <lastmod>2022-04-14T07:00:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-acquire-checkmate-pharmaceuticals-and-its</loc>
  <lastmod>2022-04-19T07:01:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-8</loc>
  <lastmod>2022-05-02T16:15:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2022-financial-and-operating</loc>
  <lastmod>2022-05-04T06:30:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/high-school-scientists-around-world-win-nearly-8m-awards</loc>
  <lastmod>2022-05-13T12:53:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-dupixentr-dupilumab-first-treatment-adults-and</loc>
  <lastmod>2022-05-20T15:15:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/evkeezar-evinacumab-phase-3-trial-demonstrates-48-ldl-c</loc>
  <lastmod>2022-05-21T07:26:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-dupixentr-dupilumab-priority-review-adults-prurigo</loc>
  <lastmod>2022-05-31T00:59:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-completes-acquisition-checkmate-pharmaceuticals</loc>
  <lastmod>2022-05-31T08:32:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-strengthens-commitment-oncology-through-purchase</loc>
  <lastmod>2022-06-02T07:30:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-dupixentr-dupilumab-first-biologic-medicine-0</loc>
  <lastmod>2022-06-07T17:00:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/intellia-and-regeneron-present-updated-interim-data-phase-1</loc>
  <lastmod>2022-06-24T07:31:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-sbla-every-16-week-dosing-regimen</loc>
  <lastmod>2022-06-29T07:30:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-completes-purchase-sanofis-stake-libtayor-cemiplimab</loc>
  <lastmod>2022-07-01T07:00:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2022-financial-and-operating</loc>
  <lastmod>2022-07-06T16:01:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-phase-3-trial-shows-positive-results</loc>
  <lastmod>2022-07-14T00:59:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2022-winners-regeneron-prize-creative</loc>
  <lastmod>2022-07-26T07:01:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-genetics-center-discovers-rare-mutations-cideb-gene</loc>
  <lastmod>2022-07-27T17:15:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/novel-costimulatory-bispecific-antibody-shows-encouraging-anti</loc>
  <lastmod>2022-08-03T09:18:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2022-financial-and-operating</loc>
  <lastmod>2022-08-03T06:30:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-9</loc>
  <lastmod>2022-08-25T16:05:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/esmo-presentations-libtayor-cemiplimab-fianlimab-and-novel</loc>
  <lastmod>2022-09-04T18:05:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/late-breaking-dupixentr-dupilumab-data-ers-2022-show-consistent</loc>
  <lastmod>2022-09-05T07:29:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/aflibercept-8-mg-meets-primary-endpoints-two-global-pivotal</loc>
  <lastmod>2022-09-08T09:01:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-late-breaking-phase-3-data-eadv-2022</loc>
  <lastmod>2022-09-08T11:29:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-call-and-webcast-esmo-2022</loc>
  <lastmod>2022-09-09T10:00:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/novel-regeneron-bispecific-antibodies-show-encouraging-anti</loc>
  <lastmod>2022-09-10T02:30:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fianlimab-lag-3-inhibitor-combined-libtayor-cemiplimab</loc>
  <lastmod>2022-09-12T02:30:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-neoadjuvant-libtayor-cemiplimab-monotherapy-data</loc>
  <lastmod>2022-09-12T04:30:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-alnylam-report-promising-data-ongoing-phase-1</loc>
  <lastmod>2022-09-15T07:01:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-dupixentr-dupilumab-phase-3-data-children-aged-6-months</loc>
  <lastmod>2022-09-15T18:39:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/intellia-and-regeneron-announce-initial-data-cardiomyopathy-arm</loc>
  <lastmod>2022-09-16T07:15:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-fda-first-and-only-treatment</loc>
  <lastmod>2022-09-28T17:44:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/aflibercept-8-mg-positive-pivotal-results-diabetic-macular-edema</loc>
  <lastmod>2022-09-30T17:04:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-elects-dr-craig-b-thompson-board-directors</loc>
  <lastmod>2022-10-03T07:00:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2022-financial-and-operating</loc>
  <lastmod>2022-10-04T16:00:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-late-breaking-phase-3-data-presented-ueg</loc>
  <lastmod>2022-10-11T00:59:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-sbla-treatment-retinopathy</loc>
  <lastmod>2022-10-12T07:00:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-receives-positive-chmp-opinion-recommending</loc>
  <lastmod>2022-10-14T07:06:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-receives-six-months-us-pediatric-exclusivity-eylear</loc>
  <lastmod>2022-10-21T07:00:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/inmazebtm-atoltivimab-maftivimab-and-odesivimab-ebgn-wins</loc>
  <lastmod>2022-10-28T16:32:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2022-financial-and-operating</loc>
  <lastmod>2022-11-03T06:30:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-presents-new-data-ash-advancing-hematology-pipeline</loc>
  <lastmod>2022-11-03T09:01:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-10</loc>
  <lastmod>2022-11-03T16:06:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/aflibercept-8-mg-late-breaking-data-presented-retina-society</loc>
  <lastmod>2022-11-04T19:30:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-rwlc-combination-chemotherapy-approved-fda</loc>
  <lastmod>2022-11-08T18:33:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-recommended-eu-approval-chmp-treatment</loc>
  <lastmod>2022-11-11T06:59:26-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-cytomx-announce-strategic-research-collaboration</loc>
  <lastmod>2022-11-17T07:00:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-european-commission-first-0</loc>
  <lastmod>2022-11-22T13:25:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/evkeezar-evinacumab-dgnb-sbla-children-ultra-rare-inherited-form</loc>
  <lastmod>2022-11-30T08:05:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-esmo-io-presentations-highlight-potential-fianlimab</loc>
  <lastmod>2022-12-01T07:00:52-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/pivotal-odronextamab-cd20xcd3-phase-2-data-patients</loc>
  <lastmod>2022-12-11T12:14:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-named-dow-jones-sustainability-world-index-fourth</loc>
  <lastmod>2022-12-12T07:30:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/node/27321</loc>
  <lastmod>2022-12-22T08:48:17-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/odronextamab-cd20xcd3-demonstrates-high-and-durable-complete</loc>
  <lastmod>2022-12-12T17:30:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-european-commission-first-and-0</loc>
  <lastmod>2022-12-15T00:59:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-recommended-eu-approval-chmp-treatment-0</loc>
  <lastmod>2022-12-16T07:29:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-41st-annual-jp-morgan</loc>
  <lastmod>2022-12-19T16:01:26-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/positive-dupixentr-dupilumab-phase-3-results-adults-and</loc>
  <lastmod>2022-12-21T17:29:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-approved-japan-advanced-or-recurrent</loc>
  <lastmod>2022-12-23T08:30:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2022-financial-and</loc>
  <lastmod>2023-01-03T16:01:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/top-40-high-school-scientists-selected-finalists-regeneron</loc>
  <lastmod>2023-01-24T14:23:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-recommended-expanded-eu-approval-chmp-treat</loc>
  <lastmod>2023-01-27T00:59:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-european-commission-first-and-1</loc>
  <lastmod>2023-01-30T01:00:41-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-11</loc>
  <lastmod>2023-01-31T16:01:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2022-financial</loc>
  <lastmod>2023-02-03T06:30:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-approved-first-pharmacologic</loc>
  <lastmod>2023-02-08T18:45:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/pozelimab-c5-antibody-bla-treatment-children-and-adults-ultra</loc>
  <lastmod>2023-02-21T07:00:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/aflibercept-8-mg-bla-treatment-wet-age-related-macular</loc>
  <lastmod>2023-02-23T07:01:06-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-combination-chemotherapy-receives-positive</loc>
  <lastmod>2023-02-24T08:44:59-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/kevzarar-sarilumab-approved-fda-first-and-only-biologic</loc>
  <lastmod>2023-02-28T20:00:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-application-treatment-chronic-spontaneous</loc>
  <lastmod>2023-03-07T01:00:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/students-win-more-18-million-2023-regeneron-science-talent</loc>
  <lastmod>2023-03-14T22:41:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-late-breaking-data-aad-show-significant</loc>
  <lastmod>2023-03-18T10:00:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-european-commission-first-and-2</loc>
  <lastmod>2023-03-21T01:59:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-approves-first-class-evkeezar-evinacumab-dgnb-young-children</loc>
  <lastmod>2023-03-22T07:00:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-demonstrates-potential-become-first-biologic</loc>
  <lastmod>2023-03-23T02:00:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sonoma-biotherapeutics-announce-collaboration</loc>
  <lastmod>2023-03-28T07:30:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-combination-chemotherapy-approved-european</loc>
  <lastmod>2023-03-29T07:00:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2023-financial-and-operating</loc>
  <lastmod>2023-04-03T16:02:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-12</loc>
  <lastmod>2023-04-11T16:00:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/aflibercept-8-mg-and-eylear-aflibercept-injection-presentations</loc>
  <lastmod>2023-04-17T07:00:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-retirement-board-chair-dr-p-roy-vagelos</loc>
  <lastmod>2023-04-17T07:30:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-alnylam-report-positive-interim-phase-1-clinical</loc>
  <lastmod>2023-04-26T16:05:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-new-and-updated-clinical-data-asco</loc>
  <lastmod>2023-05-02T12:50:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2023-financial-and-operating</loc>
  <lastmod>2023-05-04T06:31:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-applauds-supreme-courts-unanimous-opinion-striking</loc>
  <lastmod>2023-05-18T12:11:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-13</loc>
  <lastmod>2023-05-18T16:01:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/high-school-scientists-and-engineers-win-nearly-9-million</loc>
  <lastmod>2023-05-19T13:32:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-late-breaking-phase-3-copd-results-presented</loc>
  <lastmod>2023-05-21T14:19:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fianlimab-lag-3-inhibitor-combined-libtayor-cemiplimab-shows</loc>
  <lastmod>2023-05-25T17:00:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/updated-linvoseltamab-bcmaxcd3-data-pivotal-trial-demonstrates</loc>
  <lastmod>2023-05-25T17:05:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-aflibercept-8-mg</loc>
  <lastmod>2023-06-27T14:45:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/two-year-results-aflibercept-8-mg-pivotal-photon-trial</loc>
  <lastmod>2023-06-27T14:46:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2023-financial-and-operating</loc>
  <lastmod>2023-06-29T16:01:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/aflibercept-8-mg-two-year-results-pivotal-photon-trial-diabetic</loc>
  <lastmod>2023-07-29T14:25:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2023-winners-regeneron-prize-creative</loc>
  <lastmod>2023-08-01T07:00:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2023-financial-and-operating</loc>
  <lastmod>2023-08-03T06:30:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-acquire-decibel-therapeutics-strengthening-gene</loc>
  <lastmod>2023-08-09T07:31:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/two-year-pulsar-trial-results-aflibercept-8-mg-demonstrate</loc>
  <lastmod>2023-08-10T07:01:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/odronextamab-receives-ema-filing-acceptance-treatment</loc>
  <lastmod>2023-08-17T08:30:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/veopoztm-pozelimab-bbfg-receives-fda-approval-first-treatment</loc>
  <lastmod>2023-08-18T13:43:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylea-hd-aflibercept-injection-8-mg-approved-fda-treatment-wet</loc>
  <lastmod>2023-08-18T18:35:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-agreement-barda-supporting-development-next</loc>
  <lastmod>2023-08-22T14:16:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-14</loc>
  <lastmod>2023-08-23T16:05:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-updates-board-directors</loc>
  <lastmod>2023-09-08T16:45:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-planned-chief-financial-officer</loc>
  <lastmod>2023-09-08T16:46:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-completes-acquisition-decibel-therapeutics-adding</loc>
  <lastmod>2023-09-25T08:37:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-treatment-eosinophilic-esophagitis-eoe</loc>
  <lastmod>2023-09-26T01:29:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2023-financial-and-operating</loc>
  <lastmod>2023-09-28T16:05:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/odronextamab-bla-treatment-relapsedrefractory-follicular</loc>
  <lastmod>2023-09-29T08:30:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-intellia-announce-expanded-research-collaboration</loc>
  <lastmod>2023-10-03T07:00:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-hd-aflibercept-injection-8-mg-two-year-results-pivotal</loc>
  <lastmod>2023-10-05T09:45:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-showcase-progress-innovative-oncology-portfolio</loc>
  <lastmod>2023-10-15T18:05:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/together-change-genomics-and-equity-initiative-launched</loc>
  <lastmod>2023-10-18T09:01:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-builds-together-changetm-initiative-five-year-5</loc>
  <lastmod>2023-10-18T09:30:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-dupixentr-dupilumab-sbla</loc>
  <lastmod>2023-10-20T17:00:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-neoadjuvant-treatment-demonstrates</loc>
  <lastmod>2023-10-21T08:50:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-phase-3-results-show-sustained-efficacy-one</loc>
  <lastmod>2023-10-24T09:47:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-15</loc>
  <lastmod>2023-10-25T16:05:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-shares-preliminary-results-showing-gene-therapy</loc>
  <lastmod>2023-10-26T16:00:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-hd-aflibercept-injection-8-mg-data-presentations-aao</loc>
  <lastmod>2023-11-01T16:00:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2023-financial-and-operating</loc>
  <lastmod>2023-11-02T06:31:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-scientific-advancements-across-diversified</loc>
  <lastmod>2023-11-03T07:01:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-commits-34-million-over-five-years-continue-sponsor</loc>
  <lastmod>2023-11-13T09:01:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentation</loc>
  <lastmod>2023-11-15T16:05:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-significantly-reduced-copd-exacerbations</loc>
  <lastmod>2023-11-27T01:30:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-host-investor-call-and-webcast-december-14-2023</loc>
  <lastmod>2023-11-30T16:07:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-share-progress-novel-combination-therapies-oncology</loc>
  <lastmod>2023-12-07T02:31:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/updated-linvoseltamab-pivotal-data-demonstrated-strong-rates-and</loc>
  <lastmod>2023-12-11T09:56:50-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/updated-odronextamab-data-relapsedrefractory-diffuse-large-b</loc>
  <lastmod>2023-12-10T12:30:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/latest-odronextamab-data-relapsedrefractory-follicular-lymphoma</loc>
  <lastmod>2023-12-10T19:30:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-named-dow-jones-sustainability-world-index-fifth</loc>
  <lastmod>2023-12-11T07:30:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-42nd-annual-jp-morgan</loc>
  <lastmod>2023-12-18T16:05:28-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2023-financial-and</loc>
  <lastmod>2024-01-05T16:05:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-us-label-updated-data-further-supporting-use</loc>
  <lastmod>2024-01-16T07:00:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/top-40-high-school-scientists-prestigious-regeneron-science</loc>
  <lastmod>2024-01-24T14:56:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-fda-approved-first-and-only-treatment</loc>
  <lastmod>2024-01-25T15:50:25-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-formation-regeneron-cell-medicines</loc>
  <lastmod>2024-01-30T07:07:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/linvoseltamab-receives-ema-filing-acceptance-treatment</loc>
  <lastmod>2024-02-02T06:00:22-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2023-financial</loc>
  <lastmod>2024-02-02T06:30:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-16</loc>
  <lastmod>2024-02-06T16:06:05-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/japan-first-world-approve-dupixentr-dupilumab-chronic</loc>
  <lastmod>2024-02-16T00:59:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/linvoseltamab-bla-treatment-relapsedrefractory-multiple-myeloma</loc>
  <lastmod>2024-02-21T07:01:41-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-priority-review-treatment</loc>
  <lastmod>2024-02-23T01:00:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-hd-aflibercept-injection-8-mg-pivotal-data-wet-age</loc>
  <lastmod>2024-03-08T07:00:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/praluentr-alirocumab-injection-receives-fda-approval-treat</loc>
  <lastmod>2024-03-11T07:00:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/high-school-seniors-win-18-million-regeneron-science-talent</loc>
  <lastmod>2024-03-12T21:55:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-biologics-license-application</loc>
  <lastmod>2024-03-25T07:00:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2024-financial-and-operating</loc>
  <lastmod>2024-04-01T16:05:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/linvoseltamab-pivotal-data-presented-aacr-reinforce-high</loc>
  <lastmod>2024-04-07T16:00:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-advances-genetic-medicine-research-american</loc>
  <lastmod>2024-04-22T17:54:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-showcase-progress-advancing-novel-investigational</loc>
  <lastmod>2024-04-24T10:05:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-mammoth-biosciences-collaborate-pursue-next</loc>
  <lastmod>2024-04-25T07:00:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylear-hd-aflibercept-injection-8-mg-presentations-arvo</loc>
  <lastmod>2024-04-29T07:00:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2024-financial-and-operating</loc>
  <lastmod>2024-05-02T06:30:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-17</loc>
  <lastmod>2024-05-06T16:06:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/latest-db-oto-results-show-dramatically-improved-hearing-normal</loc>
  <lastmod>2024-05-08T06:01:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-priority-review-0</loc>
  <lastmod>2024-05-13T01:00:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/more-9-million-awarded-high-school-scientists-and-engineers</loc>
  <lastmod>2024-05-24T15:06:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-late-breaking-data-notus-confirmatory-phase</loc>
  <lastmod>2024-05-20T14:15:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/promising-anti-tumor-activity-novel-costimulatory-bispecific</loc>
  <lastmod>2024-05-23T17:03:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/update-fda-priority-review-dupixentr-dupilumab-treatment-copd</loc>
  <lastmod>2024-05-31T01:00:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-recommended-eu-approval-chmp-treat-patients</loc>
  <lastmod>2024-05-31T01:05:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/kevzarar-sarilumab-approved-fda-treatment-active-polyarticular</loc>
  <lastmod>2024-06-11T07:00:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/updated-linvoseltamab-data-showcase-continued-deepening</loc>
  <lastmod>2024-06-16T06:10:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-positive-phase-3-data-children-1-11-years</loc>
  <lastmod>2024-06-26T17:30:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-second-quarter-2024-financial-and-operating</loc>
  <lastmod>2024-06-27T16:06:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/odronextamab-recommended-eu-approval-chmp-treat</loc>
  <lastmod>2024-06-28T07:16:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-european-union-first-ever-targeted</loc>
  <lastmod>2024-07-03T01:00:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-2024-winners-regeneron-prize-creative</loc>
  <lastmod>2024-07-31T07:32:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2024-financial-and-operating</loc>
  <lastmod>2024-08-01T06:30:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-and</loc>
  <lastmod>2024-08-07T16:05:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-biologics-license-application-0</loc>
  <lastmod>2024-08-20T18:45:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/latest-dupixentr-dupilumab-and-itepekimab-data-ers-highlight</loc>
  <lastmod>2024-08-26T01:00:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/ordsponotm-odronextamab-approved-european-union-treatment</loc>
  <lastmod>2024-08-26T09:27:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-progress-across-its-differentiated-oncology</loc>
  <lastmod>2024-09-09T07:00:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-demonstrates-durable-survival-benefit-five</loc>
  <lastmod>2024-09-09T17:00:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-first-and-only-biologic-achieve-significant</loc>
  <lastmod>2024-09-11T00:59:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-phase-3-trial-confirms-significant</loc>
  <lastmod>2024-09-18T13:57:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-data-euretina-reinforce</loc>
  <lastmod>2024-09-11T07:01:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-us-first-and-only-treatment</loc>
  <lastmod>2024-09-13T12:15:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-recommended-eu-approval-chmp-treat</loc>
  <lastmod>2024-09-20T07:45:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-third-quarter-2024-financial-and-operating</loc>
  <lastmod>2024-09-26T16:08:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-china-first-ever-biologic-medicine</loc>
  <lastmod>2024-09-27T07:00:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-us-first-ever-biologic-medicine</loc>
  <lastmod>2024-09-27T09:36:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/three-year-results-eylea-hdr-aflibercept-injection-8-mg</loc>
  <lastmod>2024-10-18T17:07:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-late-breaking-positive-phase-3-data-chronic</loc>
  <lastmod>2024-10-24T08:02:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2024-financial-and-operating</loc>
  <lastmod>2024-10-31T06:31:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-european-union-first-and-only</loc>
  <lastmod>2024-11-06T01:00:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-18</loc>
  <lastmod>2024-11-11T16:05:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlight-pioneering-pipeline-progress-across-multiple</loc>
  <lastmod>2024-11-13T07:01:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-review-treatment-chronic</loc>
  <lastmod>2024-11-15T01:01:09-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/novel-combination-pozelimab-and-cemdisiran-poze-cemdi-achieved</loc>
  <lastmod>2024-12-07T19:01:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/odronextamab-ash-presentations-underscore-impressive-potential</loc>
  <lastmod>2024-12-09T17:46:47-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-named-dow-jones-sustainability-world-index-sixth</loc>
  <lastmod>2024-12-16T16:31:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-phase-3-trial-meets-primary</loc>
  <lastmod>2024-12-17T07:00:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-presentation-43rd-annual-jp-morgan</loc>
  <lastmod>2024-12-17T16:06:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-advance-two-factor-xi-antibodies-broad-phase-3-program</loc>
  <lastmod>2024-12-19T07:01:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-fourth-quarter-and-full-year-2024-financial-and</loc>
  <lastmod>2025-01-07T16:05:25-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-collaborates-truveta-and-leading-american-health</loc>
  <lastmod>2025-01-13T06:05:23-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/adjuvant-libtayor-cemiplimab-significantly-improves-disease-free</loc>
  <lastmod>2025-01-13T06:16:09-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-business-updates-and-highlights-broad</loc>
  <lastmod>2025-02-26T11:28:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/americas-top-40-high-school-scientists-compete-18-million-awards</loc>
  <lastmod>2025-02-26T11:07:00-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2024-financial</loc>
  <lastmod>2025-02-04T06:30:37-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/three-year-results-eylea-hdr-aflibercept-injection-8-mg-patients</loc>
  <lastmod>2025-02-08T15:55:38-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-positive-phase-3-results</loc>
  <lastmod>2025-02-26T10:53:41-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/linvoseltamab-bla-accepted-fda-review-treatment</loc>
  <lastmod>2025-02-11T07:01:19-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-19</loc>
  <lastmod>2025-02-11T16:05:28-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-priority-review-targeted</loc>
  <lastmod>2025-02-18T00:59:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/latest-db-oto-results-demonstrate-clinically-meaningful-hearing</loc>
  <lastmod>2025-02-24T15:00:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/odronextamab-bla-accepted-fda-review-treatment</loc>
  <lastmod>2025-03-07T12:47:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/linvoseltamab-recommended-eu-approval-chmp-treat</loc>
  <lastmod>2025-02-28T07:00:48-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-late-breaking-positive-pivotal-data-bullous</loc>
  <lastmod>2025-03-08T13:00:28-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/news-releases/news-release-details/regeneron-science-talent-search-2025-awards-more-18-million-high</loc>
  <lastmod>2025-03-11T22:17:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001532176-18-000010</loc>
  <lastmod>2021-03-11T20:00:20-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-18-000183</loc>
  <lastmod>2021-03-11T20:00:20-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/5/0001104659-18-007629</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0001532176-18-000013</loc>
  <lastmod>2018-07-06T08:47:59-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000932471-18-003748</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001104659-18-008557</loc>
  <lastmod>2021-03-11T20:00:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-18-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-18-001539</loc>
  <lastmod>2021-03-11T20:00:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-18-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001422849-18-000102</loc>
  <lastmod>2021-03-11T20:00:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-18-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-18-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001047469-18-003073</loc>
  <lastmod>2021-03-11T20:00:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defa14a/0001104659-18-025866</loc>
  <lastmod>2021-03-11T20:00:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defa14a/0001104659-18-025868</loc>
  <lastmod>2021-03-11T20:00:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001532176-18-000018</loc>
  <lastmod>2021-03-11T20:00:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001532176-18-000020</loc>
  <lastmod>2018-07-06T08:57:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001708138-18-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001708138-18-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001140361-18-028055</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000891836-03-000581</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-011181</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000026</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-011974</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-03-012534</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000028</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000030</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000031</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000032</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000033</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000034</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000038</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000040</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000041</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000001</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/5/0001237899-04-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000003</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/5/0001237899-04-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000895345-04-000059</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-04-000921</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001015402-04-000492</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-04-000968</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000950123-04-002024</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-04-002235</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-04-002555</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000019</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000020</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000021</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000950123-04-003254</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000023</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-ka/0000950123-04-003550</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4a/0001237899-04-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000027</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-04-005015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-04-000384</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-04-005202</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-04-005322</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-04-005343</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001254560-04-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001254560-04-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001193125-04-079147</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-04-005871</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000031</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000032</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000035</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000037</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000039</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-04-008811</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-04-009281</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-8/0000950123-04-011352</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000041</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000042</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000043</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000044</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-04-012639</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-04-013173</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-04-013538</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-04-001652</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-04-001653</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/pre-14a/0001206774-04-001651</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-c/0001206774-04-001654</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defa14a/0001206774-04-001655</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-c/0001145443-04-001897</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-04-001683</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-i/0000950123-04-014407</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-ia/0000950123-04-014459</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-04-014716</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-ka/0000950123-04-014749</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3/0000950123-04-014750</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000046</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000047</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000048</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000049</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000050</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000051</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000052</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-04-000053</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950172-04-003022</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-ia/0000950172-04-003023</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-ia/0000950172-05-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000003</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-ia/0000950172-05-000053</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950172-05-000071</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-ia/0000950172-05-000074</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000016</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-000248</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/5/0001237899-05-000017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000018</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000019</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000020</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950172-05-000381</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000021</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000022</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001104659-05-004894</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001193125-05-023401</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3a/0000950123-05-001401</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001193125-05-024957</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-05-001065</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000023</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000902219-05-001037</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000913414-05-000407</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000024</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-002144</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000026</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000950123-05-002979</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000950123-05-004013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000950123-05-004016</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950172-05-001189</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950172-05-001375</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-05-000747</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-05-005904</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-006417</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13d/0000912057-95-005657</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000912057-95-010780</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000950150-95-000590</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-96-001067</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-96-001653</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000912057-96-003913</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000912057-96-006661</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defn14a/0000940180-96-000082</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-a12g/0000950172-96-000641</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13d/0000080424-97-000040</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000080424-97-000048</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000889812-97-000079</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000889812-97-000791</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-97-001109</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000889812-97-001152</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0000889812-97-001264</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-ka/0000889812-97-001283</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-97-001703</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-97-002443</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000899140-97-000081</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-8/0000950172-97-000778</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000889812-98-000733</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-98-001229</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-98-001991</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-98-002587</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000950123-98-001058</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001024739-98-000464</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000354204-99-000597</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000889812-99-000997</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0000889812-99-001353</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defa14a/0000889812-99-001411</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-99-001510</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-99-002314</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-99-003259</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000899140-99-000257</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-8/0000950172-99-000760</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000354204-00-001046</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000889812-00-001090</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3/0000889812-00-001092</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3a/0000889812-00-001158</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b1/0000889812-00-001434</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000889812-00-001619</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0000889812-00-002043</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000898430-00-000675</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000898430-00-001166</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950172-00-000647</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-00-002227</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000895345-00-000320</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000889812-00-003433</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000080424-00-000031</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001125282-00-000582</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-01-000606</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3/0000950123-01-000607</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-ka/0000950123-01-000634</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000354204-01-001130</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000950123-01-500091</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3a/0000950123-01-500092</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000080424-01-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3a/0000950123-01-500194</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000898430-01-000923</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3a/0000950123-01-002397</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000891836-01-000086</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b4/0000950123-01-002421</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/pos-ex/0000950123-01-500272</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b1/0000950123-01-002432</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000898430-01-000993</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001015402-01-500576</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000902219-01-500002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0000950123-01-501439</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-01-502280</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-8/0000950123-01-502703</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-01-505460</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-01-507177</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-01-507186</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/pres14a/0000950123-01-508078</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-01-508241</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defs14a/0000950123-01-508707</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13da/0000895345-01-500668</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3/0000950123-01-508977</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000891836-01-500378</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3a/0000950123-01-509508</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3a/0000950123-02-000546</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-3a/0000950123-02-000590</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-02-000616</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950172-02-000172</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001021408-02-001289</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-02-001029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-02-000997</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-02-001454</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000031</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000033</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-008119</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000034</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000038</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-009421</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000040</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-05-009494</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-05-009557</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-011496</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-013047</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-05-013081</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0000950127-05-000798</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000950127-05-000799</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-014882</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000043</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000044</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000045</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000046</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000047</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000048</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000049</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000050</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-015057</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-05-015141</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-05-065747</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000058</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000059</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-05-000060</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000003</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/5/0001237899-06-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000016</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000018</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000019</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000020</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-000678</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000913414-06-001444</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-000924</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-001068</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000024</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000026</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000312069-06-001762</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001140361-06-002279</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-06-000953</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000950123-06-001686</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000950123-06-001687</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-06-002706</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-002192</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-002213</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000950123-06-002365</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000028</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000031</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000033</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-004826</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-06-000842</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-005554</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-005771</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-06-005880</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-007245</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000035</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-007528</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000037</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000038</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-009822</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-06-010084</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000042</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000044</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-011408</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-06-050323</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001237899-06-000047</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000048</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-06-055147</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4a/0001209191-06-055148</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-012721</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000050</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/15-12g/0001341004-06-002821</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-013247</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-06-013527</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-013595</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000052</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-06-058447</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000055</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000056</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b5/0000950123-06-014209</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-014213</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-014319</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000059</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-06-000060</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001336665-06-000016</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-06-015550</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000003</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000913414-07-002093</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-001413</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/5/0001209191-07-007979</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000950123-07-001484</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001104659-07-010175</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000950123-07-001972</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-07-000978</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000312348-07-000029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001237899-07-000017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000018</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000020</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000021</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-003120</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000950123-07-003627</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-004963</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000023</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000024</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000026</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000027</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000030</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-07-001113</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000031</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-006700</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-07-006735</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000950123-02-002817</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000315066-02-001525</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-02-004260</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0000950123-02-004815</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-02-004899</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-02-005298</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-02-006802</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-02-006929</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-02-007231</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-8-pos/0000950123-02-007336</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-8/0000950123-02-007337</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-02-007796</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001015402-02-003064</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-02-010532</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-02-011130</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-000476</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-000974</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-03-000922</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000891836-03-000079</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000950123-03-001386</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-03-001919</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-03-001081</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001181431-03-004353</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000950123-03-003582</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-003749</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000891836-03-000217</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001005477-03-000122</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/424b3/0000950123-03-004015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-004333</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0000950123-03-005127</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-005307</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-03-002302</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-03-006048</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001005477-03-001497</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001005477-03-001507</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-03-002515</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-008861</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-03-009451</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-03-010206</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001104659-03-020606</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000016</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000021</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000022</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000023</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000024</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-03-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-008443</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001237899-07-000035</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000037</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000038</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-010633</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-07-010794</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-011404</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001237899-07-000040</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000041</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-013232</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000043</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-014391</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-014793</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-07-062009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-014956</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000045</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000046</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000048</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000047</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-07-015042</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-015387</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-016134</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-07-070980</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000050</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000051</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000052</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000054</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000055</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000056</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000057</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000058</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000059</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-07-000060</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001181431-07-077061</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001193125-07-269851</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-07-071440</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-07-016972</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000003</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-08-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000728889-08-000259</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000913414-08-004308</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000312348-08-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-08-002036</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0000950123-08-002191</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-002251</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-002319</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-003946</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001140361-08-009406</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-08-000874</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-08-005043</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-005050</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-005993</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/ct-order/9999999997-08-026388</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001431092-08-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-006564</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001193125-08-130017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-006981</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-8/0000950123-08-007267</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-007572</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/ct-order/9999999997-08-033879</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-008608</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-08-008675</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000019</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/ct-order/9999999997-08-037235</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-010597</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000021</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000023</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000026</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000028</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-08-054077</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001431092-08-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000031</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000032</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000033</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000034</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-014344</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0000950123-08-014408</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-08-015831</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000036</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000038</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000040</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000041</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000042</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000043</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000044</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000049</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000050</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000051</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000052</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000053</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000054</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-08-000056</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000001</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000003</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0000950123-09-000448</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000728889-09-000271</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001193125-09-018680</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000913414-09-003906</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000312348-09-000034</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-09-000912</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-09-002068</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0001206774-09-000338</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-000352</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001237899-09-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-09-000860</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001206774-09-000907</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-000928</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-001178</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-001183</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000016</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000018</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-001497</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001206774-09-001498</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001431092-09-000001</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000020</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-001753</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/ct-order/9999999997-09-024828</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000022</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000024</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001206774-09-002017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-002042</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-09-003864</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-002097</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000026</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000028</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-09-002305</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000030</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000032</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000033</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000034</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000035</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000036</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000037</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000038</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000039</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000040</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000041</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000042</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000043</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000044</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-09-000046</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000001</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000003</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001086364-10-007801</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000016</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000080255-10-000093</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-10-000813</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0000315066-10-002056</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-10-000283</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0001206774-10-000298</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-10-000319</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001431092-10-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001237899-10-000019</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000020</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000021</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-10-001040</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defa14a/0001206774-10-001041</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001206774-10-001072</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-10-001084</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-10-001275</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000022</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000023</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000024</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-10-000026</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defa14a/0001206774-11-001181</loc>
  <lastmod>2021-03-11T19:53:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defa14a/0001206774-11-001317</loc>
  <lastmod>2021-03-11T19:53:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/s-8/0001206774-11-001374</loc>
  <lastmod>2021-03-11T19:53:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-001383</loc>
  <lastmod>2021-03-11T19:53:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-001412</loc>
  <lastmod>2021-03-11T19:53:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000034</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-001439</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000035</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000036</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000037</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001422849-11-000342</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000038</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000039</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000040</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000041</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000042</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001206774-11-001639</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-001641</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000043</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000044</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000045</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000046</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-001884</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000047</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-001912</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001237899-11-000048</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000049</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000050</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000052</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-11-047115</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000053</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000054</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000055</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000056</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000057</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000058</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-ka/0001206774-11-002065</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000059</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000060</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000062</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000061</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-002117</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000063</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000064</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000065</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001193125-11-273012</loc>
  <lastmod>2021-03-11T19:52:53-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001193125-11-274038</loc>
  <lastmod>2021-03-11T19:52:53-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001193125-11-278786</loc>
  <lastmod>2021-03-11T19:52:53-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001206774-11-002300</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-002304</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-002392</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-002523</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000066</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-002628</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-ka/0001206774-11-002642</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-002647</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000069</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/3/0001237899-11-000068</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000070</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000071</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-002780</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000072</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000073</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000074</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000075</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000076</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000078</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000077</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000079</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000080</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000081</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000082</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000083</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000084</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000085</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-11-000086</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-11-002936</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-12-000034</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000001</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000002</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000003</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000004</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000005</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000006</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000007</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000008</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000009</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000010</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-12-000074</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000011</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000012</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000013</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000014</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000015</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000016</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-ka/0001206774-12-000199</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000017</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000018</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13g/0001193125-12-042488</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000020</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001086364-12-000233</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0001422849-12-000295</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-12-000566</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000080255-12-000403</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/5/0001237899-12-000023</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000902219-12-000377</loc>
  <lastmod>2021-03-11T19:51:47-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/sc-13ga/0000315066-12-002976</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000024</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000025</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000026</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000027</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000028</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000029</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-k/0001206774-12-000709</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000030</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000031</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000032</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000034</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000035</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000036</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/ct-order/9999999997-12-007597</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000047</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/def-14a/0001206774-12-001697</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/defa14a/0001206774-12-001698</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/10-q/0001206774-12-001689</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001206774-12-001690</loc>
  <lastmod>2021-03-11T19:53:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000050</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000051</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000052</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001209191-12-025352</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000054</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001193125-12-216794</loc>
  <lastmod>2021-03-11T19:52:53-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000056</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000057</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000058</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/4/0001237899-12-000059</loc>
  <lastmod>2021-07-09T20:00:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.regeneron.com/sec-filings/sec-filing/8-k/0001193125-12-271011</loc>
  <lastmod>2021-03-11T19:52:53-05:00</lastmod>
  <priority>0.4</priority>
 </url>
</urlset>
